|
||||||
|
 | Fusion Gene Summary |
| Fusion Gene ORF analysis |
| Fusion Genomic Features |
| Fusion Protein Features |
| Fusion Gene Sequence |
| Fusion Gene PPI analysis |
| Related Drugs |
| Related Diseases |
Fusion gene:ARHGAP35-ESR1 (FusionGDB2 ID:6190) |
Fusion Gene Summary for ARHGAP35-ESR1 |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: ARHGAP35-ESR1 | Fusion gene ID: 6190 | Hgene | Tgene | Gene symbol | ARHGAP35 | ESR1 | Gene ID | 2909 | 2099 |
| Gene name | Rho GTPase activating protein 35 | estrogen receptor 1 | |
| Synonyms | GRF-1|GRLF1|P190-A|P190A|p190ARhoGAP|p190RhoGAP | ER|ESR|ESRA|ESTRR|Era|NR3A1 | |
| Cytomap | 19q13.32 | 6q25.1-q25.2 | |
| Type of gene | protein-coding | protein-coding | |
| Description | rho GTPase-activating protein 35glucocorticoid receptor DNA-binding factor 1glucocorticoid receptor repression factor 1rho GAP p190A | estrogen receptorE2 receptor alphaER-alphaestradiol receptorestrogen nuclear receptor alphaestrogen receptor alpha E1-E2-1-2estrogen receptor alpha E1-N2-E2-1-2nuclear receptor subfamily 3 group A member 1oestrogen receptor alpha | |
| Modification date | 20200313 | 20200329 | |
| UniProtAcc | Q9NRY4 | P03372 | |
| Ensembl transtripts involved in fusion gene | ENST00000404338, ENST00000598548, | ENST00000440973, ENST00000338799, ENST00000456483, ENST00000443427, ENST00000206249, ENST00000406599, ENST00000427531, ENST00000482101, | |
| Fusion gene scores | * DoF score | 19 X 11 X 9=1881 | 10 X 10 X 6=600 |
| # samples | 19 | 12 | |
| ** MAII score | log2(19/1881*10)=-3.30742852519225 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(12/600*10)=-2.32192809488736 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
| Context | PubMed: ARHGAP35 [Title/Abstract] AND ESR1 [Title/Abstract] AND fusion [Title/Abstract] | ||
| Most frequent breakpoint | ARHGAP35(47440665)-ESR1(152201789), # samples:1 | ||
| Anticipated loss of major functional domain due to fusion event. | |||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Tgene | ESR1 | GO:0006366 | transcription by RNA polymerase II | 15831516 |
| Tgene | ESR1 | GO:0010629 | negative regulation of gene expression | 21695196 |
| Tgene | ESR1 | GO:0030520 | intracellular estrogen receptor signaling pathway | 9841876 |
| Tgene | ESR1 | GO:0032355 | response to estradiol | 15304487 |
| Tgene | ESR1 | GO:0043124 | negative regulation of I-kappaB kinase/NF-kappaB signaling | 7651415|16043358 |
| Tgene | ESR1 | GO:0043433 | negative regulation of DNA-binding transcription factor activity | 10816575 |
| Tgene | ESR1 | GO:0043627 | response to estrogen | 11581164 |
| Tgene | ESR1 | GO:0045893 | positive regulation of transcription, DNA-templated | 9841876|20074560 |
| Tgene | ESR1 | GO:0045899 | positive regulation of RNA polymerase II transcriptional preinitiation complex assembly | 9841876 |
| Tgene | ESR1 | GO:0045944 | positive regulation of transcription by RNA polymerase II | 11544182|12047722|15345745|15831516|18563714 |
| Tgene | ESR1 | GO:0051091 | positive regulation of DNA-binding transcription factor activity | 9328340|10681512 |
| Tgene | ESR1 | GO:0071392 | cellular response to estradiol stimulus | 15831516 |
| Fusion gene breakpoints across ARHGAP35 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
| Fusion gene breakpoints across ESR1 (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
| Fusion gene information from two resources (ChiTars 5.0 and ChimerDB 4.0) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| ChimerDB4 | BRCA | TCGA-A8-A06O | ARHGAP35 | chr19 | 47440665 | + | ESR1 | chr6 | 152201789 | + |
Top |
Fusion Gene ORF analysis for ARHGAP35-ESR1 |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| In-frame | ENST00000404338 | ENST00000440973 | ARHGAP35 | chr19 | 47440665 | + | ESR1 | chr6 | 152201789 | + |
| In-frame | ENST00000404338 | ENST00000338799 | ARHGAP35 | chr19 | 47440665 | + | ESR1 | chr6 | 152201789 | + |
| In-frame | ENST00000404338 | ENST00000456483 | ARHGAP35 | chr19 | 47440665 | + | ESR1 | chr6 | 152201789 | + |
| In-frame | ENST00000404338 | ENST00000443427 | ARHGAP35 | chr19 | 47440665 | + | ESR1 | chr6 | 152201789 | + |
| In-frame | ENST00000404338 | ENST00000206249 | ARHGAP35 | chr19 | 47440665 | + | ESR1 | chr6 | 152201789 | + |
| 5CDS-intron | ENST00000404338 | ENST00000406599 | ARHGAP35 | chr19 | 47440665 | + | ESR1 | chr6 | 152201789 | + |
| 5CDS-intron | ENST00000404338 | ENST00000427531 | ARHGAP35 | chr19 | 47440665 | + | ESR1 | chr6 | 152201789 | + |
| 5CDS-intron | ENST00000404338 | ENST00000482101 | ARHGAP35 | chr19 | 47440665 | + | ESR1 | chr6 | 152201789 | + |
| intron-3CDS | ENST00000598548 | ENST00000440973 | ARHGAP35 | chr19 | 47440665 | + | ESR1 | chr6 | 152201789 | + |
| intron-3CDS | ENST00000598548 | ENST00000338799 | ARHGAP35 | chr19 | 47440665 | + | ESR1 | chr6 | 152201789 | + |
| intron-3CDS | ENST00000598548 | ENST00000456483 | ARHGAP35 | chr19 | 47440665 | + | ESR1 | chr6 | 152201789 | + |
| intron-3CDS | ENST00000598548 | ENST00000443427 | ARHGAP35 | chr19 | 47440665 | + | ESR1 | chr6 | 152201789 | + |
| intron-3CDS | ENST00000598548 | ENST00000206249 | ARHGAP35 | chr19 | 47440665 | + | ESR1 | chr6 | 152201789 | + |
| intron-intron | ENST00000598548 | ENST00000406599 | ARHGAP35 | chr19 | 47440665 | + | ESR1 | chr6 | 152201789 | + |
| intron-intron | ENST00000598548 | ENST00000427531 | ARHGAP35 | chr19 | 47440665 | + | ESR1 | chr6 | 152201789 | + |
| intron-intron | ENST00000598548 | ENST00000482101 | ARHGAP35 | chr19 | 47440665 | + | ESR1 | chr6 | 152201789 | + |
| ORFfinder result based on the fusion transcript sequence of in-frame fusion genes. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
| ENST00000404338 | ARHGAP35 | chr19 | 47440665 | + | ENST00000440973 | ESR1 | chr6 | 152201789 | + | 9279 | 3826 | 0 | 4970 | 1656 |
| ENST00000404338 | ARHGAP35 | chr19 | 47440665 | + | ENST00000338799 | ESR1 | chr6 | 152201789 | + | 5058 | 3826 | 0 | 4970 | 1656 |
| ENST00000404338 | ARHGAP35 | chr19 | 47440665 | + | ENST00000456483 | ESR1 | chr6 | 152201789 | + | 8943 | 3826 | 0 | 4634 | 1544 |
| ENST00000404338 | ARHGAP35 | chr19 | 47440665 | + | ENST00000443427 | ESR1 | chr6 | 152201789 | + | 9279 | 3826 | 0 | 4970 | 1656 |
| ENST00000404338 | ARHGAP35 | chr19 | 47440665 | + | ENST00000206249 | ESR1 | chr6 | 152201789 | + | 9276 | 3826 | 0 | 4970 | 1656 |
| DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
| ENST00000404338 | ENST00000440973 | ARHGAP35 | chr19 | 47440665 | + | ESR1 | chr6 | 152201789 | + | 0.000241956 | 0.99975806 |
| ENST00000404338 | ENST00000338799 | ARHGAP35 | chr19 | 47440665 | + | ESR1 | chr6 | 152201789 | + | 0.000835508 | 0.99916446 |
| ENST00000404338 | ENST00000456483 | ARHGAP35 | chr19 | 47440665 | + | ESR1 | chr6 | 152201789 | + | 0.000138792 | 0.99986124 |
| ENST00000404338 | ENST00000443427 | ARHGAP35 | chr19 | 47440665 | + | ESR1 | chr6 | 152201789 | + | 0.000241956 | 0.99975806 |
| ENST00000404338 | ENST00000206249 | ARHGAP35 | chr19 | 47440665 | + | ESR1 | chr6 | 152201789 | + | 0.000242933 | 0.9997571 |
Top |
Fusion Genomic Features for ARHGAP35-ESR1 |
| FusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints. |
| Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | 1-p | p (fusion gene breakpoint) |
| ARHGAP35 | chr19 | 47440665 | + | ESR1 | chr6 | 152201789 | + | 9.20E-08 | 0.9999999 |
| ARHGAP35 | chr19 | 47440665 | + | ESR1 | chr6 | 152201789 | + | 9.20E-08 | 0.9999999 |
| Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions. We integrated a total of 44 different types of human genomic feature loci information across five big categories including virus integration sites, repeats, structural variants, chromatin states, and gene expression regulation. More details are in help page. |
| Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions that are ovelapped with the top 1% feature importance score regions. More details are in help page. |
Top |
Fusion Protein Features for ARHGAP35-ESR1 |
| Go to FGviewer for the breakpoints of chr19:47440665-chr6:152201789 - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. |
 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| ARHGAP35 | ESR1 |
| FUNCTION: Rho GTPase-activating protein (GAP) (PubMed:19673492, PubMed:28894085). Binds several acidic phospholipids which inhibits the Rho GAP activity to promote the Rac GAP activity (PubMed:19673492). This binding is inhibited by phosphorylation by PRKCA (PubMed:19673492). Involved in cell differentiation as well as cell adhesion and migration, plays an important role in retinal tissue morphogenesis, neural tube fusion, midline fusion of the cerebral hemispheres and mammary gland branching morphogenesis (By similarity). Transduces signals from p21-ras to the nucleus, acting via the ras GTPase-activating protein (GAP) (By similarity). Transduces SRC-dependent signals from cell-surface adhesion molecules, such as laminin, to promote neurite outgrowth. Regulates axon outgrowth, guidance and fasciculation (By similarity). Modulates Rho GTPase-dependent F-actin polymerization, organization and assembly, is involved in polarized cell migration and in the positive regulation of ciliogenesis and cilia elongation (By similarity). During mammary gland development, is required in both the epithelial and stromal compartments for ductal outgrowth (By similarity). Represses transcription of the glucocorticoid receptor by binding to the cis-acting regulatory sequence 5'-GAGAAAAGAAACTGGAGAAACTC-3'; this function is however unclear and would need additional experimental evidences (PubMed:1894621). {ECO:0000250|UniProtKB:P81128, ECO:0000250|UniProtKB:Q91YM2, ECO:0000269|PubMed:1894621, ECO:0000269|PubMed:19673492, ECO:0000269|PubMed:28894085}. | FUNCTION: Nuclear hormone receptor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Ligand-dependent nuclear transactivation involves either direct homodimer binding to a palindromic estrogen response element (ERE) sequence or association with other DNA-binding transcription factors, such as AP-1/c-Jun, c-Fos, ATF-2, Sp1 and Sp3, to mediate ERE-independent signaling. Ligand binding induces a conformational change allowing subsequent or combinatorial association with multiprotein coactivator complexes through LXXLL motifs of their respective components. Mutual transrepression occurs between the estrogen receptor (ER) and NF-kappa-B in a cell-type specific manner. Decreases NF-kappa-B DNA-binding activity and inhibits NF-kappa-B-mediated transcription from the IL6 promoter and displace RELA/p65 and associated coregulators from the promoter. Recruited to the NF-kappa-B response element of the CCL2 and IL8 promoters and can displace CREBBP. Present with NF-kappa-B components RELA/p65 and NFKB1/p50 on ERE sequences. Can also act synergistically with NF-kappa-B to activate transcription involving respective recruitment adjacent response elements; the function involves CREBBP. Can activate the transcriptional activity of TFF1. Also mediates membrane-initiated estrogen signaling involving various kinase cascades. Isoform 3 is involved in activation of NOS3 and endothelial nitric oxide production. Isoforms lacking one or several functional domains are thought to modulate transcriptional activity by competitive ligand or DNA binding and/or heterodimerization with the full-length receptor. Essential for MTA1-mediated transcriptional regulation of BRCA1 and BCAS3. Isoform 3 can bind to ERE and inhibit isoform 1. {ECO:0000269|PubMed:10681512, ECO:0000269|PubMed:10816575, ECO:0000269|PubMed:11477071, ECO:0000269|PubMed:11682626, ECO:0000269|PubMed:14764652, ECO:0000269|PubMed:15078875, ECO:0000269|PubMed:15891768, ECO:0000269|PubMed:16043358, ECO:0000269|PubMed:16617102, ECO:0000269|PubMed:16684779, ECO:0000269|PubMed:17922032, ECO:0000269|PubMed:17932106, ECO:0000269|PubMed:18247370, ECO:0000269|PubMed:19350539, ECO:0000269|PubMed:20074560, ECO:0000269|PubMed:20705611, ECO:0000269|PubMed:21330404, ECO:0000269|PubMed:22083956, ECO:0000269|PubMed:7651415, ECO:0000269|PubMed:9328340}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| Hgene | ARHGAP35 | chr19:47440665 | chr6:152201789 | ENST00000404338 | + | 2 | 6 | 270_327 | 1275.3333333333333 | 1500.0 | Domain | Note=FF 1 |
| Hgene | ARHGAP35 | chr19:47440665 | chr6:152201789 | ENST00000404338 | + | 2 | 6 | 368_422 | 1275.3333333333333 | 1500.0 | Domain | Note=FF 2 |
| Hgene | ARHGAP35 | chr19:47440665 | chr6:152201789 | ENST00000404338 | + | 2 | 6 | 429_483 | 1275.3333333333333 | 1500.0 | Domain | Note=FF 3 |
| Hgene | ARHGAP35 | chr19:47440665 | chr6:152201789 | ENST00000404338 | + | 2 | 6 | 485_550 | 1275.3333333333333 | 1500.0 | Domain | Note=FF 4 |
| Hgene | ARHGAP35 | chr19:47440665 | chr6:152201789 | ENST00000404338 | + | 2 | 6 | 592_767 | 1275.3333333333333 | 1500.0 | Domain | pG1 pseudoGTPase |
| Hgene | ARHGAP35 | chr19:47440665 | chr6:152201789 | ENST00000404338 | + | 2 | 6 | 783_947 | 1275.3333333333333 | 1500.0 | Domain | pG2 pseudoGTPase |
| Hgene | ARHGAP35 | chr19:47440665 | chr6:152201789 | ENST00000404338 | + | 2 | 6 | 201_203 | 1275.3333333333333 | 1500.0 | Nucleotide binding | GTP |
| Hgene | ARHGAP35 | chr19:47440665 | chr6:152201789 | ENST00000404338 | + | 2 | 6 | 229_231 | 1275.3333333333333 | 1500.0 | Nucleotide binding | GTP |
| Hgene | ARHGAP35 | chr19:47440665 | chr6:152201789 | ENST00000404338 | + | 2 | 6 | 33_37 | 1275.3333333333333 | 1500.0 | Nucleotide binding | GTP |
| Hgene | ARHGAP35 | chr19:47440665 | chr6:152201789 | ENST00000404338 | + | 2 | 6 | 95_97 | 1275.3333333333333 | 1500.0 | Nucleotide binding | GTP |
| Hgene | ARHGAP35 | chr19:47440665 | chr6:152201789 | ENST00000404338 | + | 2 | 6 | 1213_1236 | 1275.3333333333333 | 1500.0 | Region | Required for phospholipid binding and regulation of the substrate preference |
| Hgene | ARHGAP35 | chr19:47440665 | chr6:152201789 | ENST00000404338 | + | 2 | 6 | 1_266 | 1275.3333333333333 | 1500.0 | Region | Has GTPase activity%2C required for proper localization |
| Tgene | ESR1 | chr19:47440665 | chr6:152201789 | ENST00000206249 | 1 | 8 | 311_547 | 214.33333333333334 | 596.0 | Domain | NR LBD | |
| Tgene | ESR1 | chr19:47440665 | chr6:152201789 | ENST00000338799 | 2 | 9 | 311_547 | 214.33333333333334 | 596.0 | Domain | NR LBD | |
| Tgene | ESR1 | chr19:47440665 | chr6:152201789 | ENST00000440973 | 3 | 10 | 311_547 | 214.33333333333334 | 596.0 | Domain | NR LBD | |
| Tgene | ESR1 | chr19:47440665 | chr6:152201789 | ENST00000443427 | 2 | 9 | 311_547 | 214.33333333333334 | 596.0 | Domain | NR LBD | |
| Tgene | ESR1 | chr19:47440665 | chr6:152201789 | ENST00000456483 | 2 | 8 | 311_547 | 214.33333333333334 | 484.0 | Domain | NR LBD | |
| Tgene | ESR1 | chr19:47440665 | chr6:152201789 | ENST00000206249 | 1 | 8 | 251_310 | 214.33333333333334 | 596.0 | Region | Note=Hinge | |
| Tgene | ESR1 | chr19:47440665 | chr6:152201789 | ENST00000206249 | 1 | 8 | 264_595 | 214.33333333333334 | 596.0 | Region | Note=Self-association | |
| Tgene | ESR1 | chr19:47440665 | chr6:152201789 | ENST00000206249 | 1 | 8 | 311_595 | 214.33333333333334 | 596.0 | Region | Note=Transactivation AF-2 | |
| Tgene | ESR1 | chr19:47440665 | chr6:152201789 | ENST00000338799 | 2 | 9 | 251_310 | 214.33333333333334 | 596.0 | Region | Note=Hinge | |
| Tgene | ESR1 | chr19:47440665 | chr6:152201789 | ENST00000338799 | 2 | 9 | 264_595 | 214.33333333333334 | 596.0 | Region | Note=Self-association | |
| Tgene | ESR1 | chr19:47440665 | chr6:152201789 | ENST00000338799 | 2 | 9 | 311_595 | 214.33333333333334 | 596.0 | Region | Note=Transactivation AF-2 | |
| Tgene | ESR1 | chr19:47440665 | chr6:152201789 | ENST00000440973 | 3 | 10 | 251_310 | 214.33333333333334 | 596.0 | Region | Note=Hinge | |
| Tgene | ESR1 | chr19:47440665 | chr6:152201789 | ENST00000440973 | 3 | 10 | 264_595 | 214.33333333333334 | 596.0 | Region | Note=Self-association | |
| Tgene | ESR1 | chr19:47440665 | chr6:152201789 | ENST00000440973 | 3 | 10 | 311_595 | 214.33333333333334 | 596.0 | Region | Note=Transactivation AF-2 | |
| Tgene | ESR1 | chr19:47440665 | chr6:152201789 | ENST00000443427 | 2 | 9 | 251_310 | 214.33333333333334 | 596.0 | Region | Note=Hinge | |
| Tgene | ESR1 | chr19:47440665 | chr6:152201789 | ENST00000443427 | 2 | 9 | 264_595 | 214.33333333333334 | 596.0 | Region | Note=Self-association | |
| Tgene | ESR1 | chr19:47440665 | chr6:152201789 | ENST00000443427 | 2 | 9 | 311_595 | 214.33333333333334 | 596.0 | Region | Note=Transactivation AF-2 | |
| Tgene | ESR1 | chr19:47440665 | chr6:152201789 | ENST00000456483 | 2 | 8 | 251_310 | 214.33333333333334 | 484.0 | Region | Note=Hinge | |
| Tgene | ESR1 | chr19:47440665 | chr6:152201789 | ENST00000456483 | 2 | 8 | 264_595 | 214.33333333333334 | 484.0 | Region | Note=Self-association | |
| Tgene | ESR1 | chr19:47440665 | chr6:152201789 | ENST00000456483 | 2 | 8 | 311_595 | 214.33333333333334 | 484.0 | Region | Note=Transactivation AF-2 | |
| Tgene | ESR1 | chr19:47440665 | chr6:152201789 | ENST00000206249 | 1 | 8 | 221_245 | 214.33333333333334 | 596.0 | Zinc finger | NR C4-type | |
| Tgene | ESR1 | chr19:47440665 | chr6:152201789 | ENST00000338799 | 2 | 9 | 221_245 | 214.33333333333334 | 596.0 | Zinc finger | NR C4-type | |
| Tgene | ESR1 | chr19:47440665 | chr6:152201789 | ENST00000440973 | 3 | 10 | 221_245 | 214.33333333333334 | 596.0 | Zinc finger | NR C4-type | |
| Tgene | ESR1 | chr19:47440665 | chr6:152201789 | ENST00000443427 | 2 | 9 | 221_245 | 214.33333333333334 | 596.0 | Zinc finger | NR C4-type | |
| Tgene | ESR1 | chr19:47440665 | chr6:152201789 | ENST00000456483 | 2 | 8 | 221_245 | 214.33333333333334 | 484.0 | Zinc finger | NR C4-type |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| Hgene | ARHGAP35 | chr19:47440665 | chr6:152201789 | ENST00000404338 | + | 2 | 6 | 1440_1490 | 1275.3333333333333 | 1500.0 | Compositional bias | Note=Pro-rich |
| Hgene | ARHGAP35 | chr19:47440665 | chr6:152201789 | ENST00000404338 | + | 2 | 6 | 1249_1436 | 1275.3333333333333 | 1500.0 | Domain | Rho-GAP |
| Tgene | ESR1 | chr19:47440665 | chr6:152201789 | ENST00000206249 | 1 | 8 | 185_250 | 214.33333333333334 | 596.0 | DNA binding | Nuclear receptor | |
| Tgene | ESR1 | chr19:47440665 | chr6:152201789 | ENST00000338799 | 2 | 9 | 185_250 | 214.33333333333334 | 596.0 | DNA binding | Nuclear receptor | |
| Tgene | ESR1 | chr19:47440665 | chr6:152201789 | ENST00000440973 | 3 | 10 | 185_250 | 214.33333333333334 | 596.0 | DNA binding | Nuclear receptor | |
| Tgene | ESR1 | chr19:47440665 | chr6:152201789 | ENST00000443427 | 2 | 9 | 185_250 | 214.33333333333334 | 596.0 | DNA binding | Nuclear receptor | |
| Tgene | ESR1 | chr19:47440665 | chr6:152201789 | ENST00000456483 | 2 | 8 | 185_250 | 214.33333333333334 | 484.0 | DNA binding | Nuclear receptor | |
| Tgene | ESR1 | chr19:47440665 | chr6:152201789 | ENST00000206249 | 1 | 8 | 185_205 | 214.33333333333334 | 596.0 | Zinc finger | NR C4-type | |
| Tgene | ESR1 | chr19:47440665 | chr6:152201789 | ENST00000338799 | 2 | 9 | 185_205 | 214.33333333333334 | 596.0 | Zinc finger | NR C4-type | |
| Tgene | ESR1 | chr19:47440665 | chr6:152201789 | ENST00000440973 | 3 | 10 | 185_205 | 214.33333333333334 | 596.0 | Zinc finger | NR C4-type | |
| Tgene | ESR1 | chr19:47440665 | chr6:152201789 | ENST00000443427 | 2 | 9 | 185_205 | 214.33333333333334 | 596.0 | Zinc finger | NR C4-type | |
| Tgene | ESR1 | chr19:47440665 | chr6:152201789 | ENST00000456483 | 2 | 8 | 185_205 | 214.33333333333334 | 484.0 | Zinc finger | NR C4-type |
Top |
Fusion Gene Sequence for ARHGAP35-ESR1 |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
| >In-frame_ENST00000404338_ENST00000440973_TCGA-A8-A06O_ARHGAP35_chr19_47440665_+_ESR1_chr6_152201789_length(transcript)=9279nt_BP=3826nt ATGATGATGGCAAGAAAGCAAGATGTCCGAATTCCCACCTACAACATCAGTGTGGTGGGATTATCTGGGACCGAGAAGGAAAAGGGCCAG TGTGGGATTGGAAAGTCTTGTTTGTGCAACCGCTTCGTGCGCCCGAGTGCTGACGAGTTTCACTTGGACCATACCTCCGTCCTCAGCACC AGTGACTTTGGAGGGCGAGTGGTCAATAATGACCACTTTCTCTACTGGGGAGAAGTTAGCCGCTCCCTGGAGGATTGTGTGGAATGTAAG ATGCACATTGTGGAGCAGACTGAATTTATTGATGATCAGACTTTTCAACCTCATCGAAGCACGGCCCTGCAGCCCTATATCAAGAGAGCT GCTGCGACCAAGCTTGCATCAGCTGAAAAACTCATGTACTTTTGCACTGACCAGCTGGGGCTGGAGCAGGACTTTGAGCAGAAACAAATG CCAGACGGAAAGCTGCTGGTTGATGGTTTTCTTCTTGGTATTGATGTTAGCAGGGGCATGAATAGGAACTTTGATGACCAGCTCAAGTTT GTCTCCAATCTCTACAATCAGCTTGCAAAAACAAAAAAGCCCATAGTGGTGGTCCTGACTAAGTGTGACGAAGGTGTTGAGCGGTACATT AGAGATGCACATACTTTTGCCTTAAGCAAAAAGAACCTCCAGGTTGTGGAGACCTCAGCGAGATCCAATGTAAACGTGGACTTGGCTTTC AGCACCTTAGTGCAACTCATTGATAAAAGTCGGGGAAAGACAAAAATCATTCCTTATTTTGAAGCTCTCAAGCAGCAGAGTCAGCAGATA GCTACAGCAAAAGACAAGTATGAGTGGCTGGTGAGTCGCATTGTGAAAAACCACAATGAGAACTGGCTGAGTGTCAGCCGAAAGATGCAG GCCTCTCCAGAATACCAGGACTATGTCTACCTGGAAGGGACTCAGAAAGCCAAGAAGCTGTTTCTACAGCACATCCACCGCCTCAAGCAT GAGCATATCGAGCGTAGGAGAAAGCTGTACCTGGCAGCCCTGCCATTAGCTTTTGAAGCTCTTATACCTAATCTAGATGAAATAGACCAC CTAAGCTGCATAAAAGCCAAAAAGCTCTTAGAAACCAAGCCAGAATTCTTGAAGTGGTTTGTTGTGCTTGAAGAGACCCCATGGGATGCC ACCAGTCACATTGACAACATGGAAAACGAACGGATTCCCTTTGATTTAATGGATACCGTCCCTGCAGAGCAGCTATACGAGGCCCACTTA GAGAAGCTGAGGAACGAAAGGAAAAGAGTTGAGATGCGAAGGGCGTTTAAAGAAAACCTGGAGACTTCTCCTTTCATAACTCCCGGAAAG CCTTGGGAAGAGGCCCGTAGTTTTATTATGAATGAGGATTTCTACCAGTGGCTGGAGGAATCTGTATACATGGATATTTATGGCAAACAC CAAAAGCAAATTATAGATAAAGCAAAGGAAGAATTTCAGGAGTTGCTTTTGGAATATTCAGAATTGTTTTATGAACTGGAGCTGGATGCT AAGCCCAGCAAGGAGAAGATGGGTGTTATTCAGGATGTTCTGGGAGAGGAACAGCGATTTAAAGCATTACAAAAGCTCCAAGCAGAGCGT GATGCCCTTATTCTGAAACACATTCATTTTGTGTACCACCCAACAAAGGAGACATGCCCCAGCTGCCCAGCTTGTGTGGACGCTAAGATT GAGCACTTGATTAGTTCTCGGTTTATCCGGCCGTCTGACCGGAATCAGAAAAATTCACTCTCTGACCCTAACATTGATAGAATCAACTTG GTTATATTGGGCAAAGACGGCCTTGCCCGAGAGTTGGCCAATGAGATTCGAGCTCTTTGTACAAATGATGACAAGTATGTGATAGATGGT AAAATGTATGAGCTTTCCCTGAGGCCAATAGAGGGGAATGTCAGGCTTCCTGTGAACTCTTTCCAGACGCCAACATTTCAGCCCCACGGC TGTCTCTGCCTTTACAATTCAAAGGAATCGCTATCCTATGTAGTGGAAAGTATAGAGAAGAGTAGAGAGTCCACGCTGGGCCGGCGGGAT AATCATTTAGTCCATCTCCCCCTTACATTAATTTTGGTTAACAAGAGAGGAGACACCAGTGGAGAGACTCTGCATAGCTTAATACAGCAA GGTCAACAAATTGCTAGCAAACTTCAGTGTGTCTTTCTCGACCCTGCTTCTGCTGGCATTGGTTACGGACGCAACATTAATGAAAAGCAA ATCAGTCAAGTTTTGAAGGGACTCCTGGACTCTAAGCGTAACTTAAACCTGGTCAGTTCTACTGCTAGCATCAAAGATTTGGCTGATGTT GATCTGCGAATTGTTATGTGTCTGATGTGTGGAGATCCTTTTAGTGCAGATGACATACTTTTTCCTGTCCTTCAGTCCCAAACCTGTAAA TCTTCCCATTGTGGAAGCAACAACTCTGTTTTACTTGAACTACCAATCGGACTGCACAAGAAGCGGATTGAACTGTCTGTTCTTTCATAC CATTCCTCCTTTAGCATCAGAAAGAGCCGGTTGGTTCATGGGTACATTGTTTTTTATTCAGCCAAACGTAAGGCCTCTTTGGCTATGTTA CGTGCCTTTCTTTGTGAAGTGCAGGATATTATCCCTATTCAGCTTGTAGCACTCACTGATGGCGCTGTAGATGTCCTGGACAATGACTTA AGTAGGGAACAGCTAACTGAGGGGGAGGAGATTGCTCAAGAAATTGACGGAAGGTTCACAAGCATCCCCTGTAGCCAACCCCAGCATAAA CTTGAGATCTTTCACCCATTTTTTAAAGATGTGGTGGAAAAAAAGAACATAATCGAGGCTACTCATATGTACGATAATGCTGCCGAGGCC TGTAGCACCACCGAAGAGGTGTTTAACTCCCCCCGGGCAGGATCACCGCTCTGCAACTCAAACCTGCAGGATTCAGAAGAAGATATCGAG CCATCTTACAGCCTGTTTCGAGAAGACACATCACTGCCTTCTCTGTCCAAAGACCATTCTAAGCTCTCTATGGAACTGGAGGGAAATGAT GGGCTGTCTTTCATTATGAGCAATTTTGAGAGTAAACTGAACAACAAAGTACCTCCGCCAGTCAAACCAAAGCCTCCTGTCCATTTTGAA ATTACAAAGGGGGATCTATCTTATTTAGACCAAGGCCATAGGGATGGACAGAGGAAGTCTGTGTCTTCTAGCCCCTGGCTGCCTCAGGAT GGGTTTGATCCTTCTGACTATGCTGAACCCATGGATGCTGTGGTGAAGCCAAGGAATGAAGAAGAAAACATATACTCCGTGCCCCATGAC AGCACCCAAGGCAAAATCATCACCATTCGGAATATCAACAAAGCCCAGTCCAACGGCAGCGGGAATGGTTCTGACAGTGAAATGGACACC AGCTCTCTAGAGCGAGGGCGCAAGGTTTCCATCGTGAGCAAGCCAGTGCTGTACAGGACGAGATGCACCCGGCTGGGGCGGTTTGCTAGT TACCGGACCAGCTTCAGCGTGGGGAGTGATGATGAGCTGGGGCCCATCCGGAAGAAAGAGGAGGATCAGGCATCCCAGGGTTATAAAGGG GACAATGCTGTCATTCCATACGAAACAGACGAAGACCCGCGGAGGAGGAATATTCTTCGCAGCCTAAGGAGGAACACTAAGAAACCAAAG CCCAAACCCCGGCCATCCATCACAAAGGCAACCTGGGAGAGTAACTATTTTGGGGTGCCCTTAACAACTGTCGTGACTCCAGAGAAGCCG ATCCCCATTTTTATTGAAAGATGTATTGAGTACATTGAAGCCACAGGACATAACGACTATATGTGTCCAGCCACCAACCAGTGCACCATT GATAAAAACAGGAGGAAGAGCTGCCAGGCCTGCCGGCTCCGTAAATGCTACGAAGTGGGAATGATGAAAGGTGGGATACGAAAAGACCGA AGAGGAGGGAGAATGTTGAAACACAAGCGCCAGAGAGATGATGGGGAGGGCAGGGGTGAAGTGGGGTCTGCTGGAGACATGAGAGCTGCC AACCTTTGGCCAAGCCCGCTCATGATCAAACGCTCTAAGAAGAACAGCCTGGCCTTGTCCCTGACGGCCGACCAGATGGTCAGTGCCTTG TTGGATGCTGAGCCCCCGATACTCTATTCCGAGTATGATCCTACCAGACCCTTCAGTGAAGCTTCGATGATGGGCTTACTGACCAACCTG GCAGACAGGGAGCTGGTTCACATGATCAACTGGGCGAAGAGGGTGCCAGGCTTTGTGGATTTGACCCTCCATGATCAGGTCCACCTTCTA GAATGTGCCTGGCTAGAGATCCTGATGATTGGTCTCGTCTGGCGCTCCATGGAGCACCCAGGGAAGCTACTGTTTGCTCCTAACTTGCTC TTGGACAGGAACCAGGGAAAATGTGTAGAGGGCATGGTGGAGATCTTCGACATGCTGCTGGCTACATCATCTCGGTTCCGCATGATGAAT CTGCAGGGAGAGGAGTTTGTGTGCCTCAAATCTATTATTTTGCTTAATTCTGGAGTGTACACATTTCTGTCCAGCACCCTGAAGTCTCTG GAAGAGAAGGACCATATCCACCGAGTCCTGGACAAGATCACAGACACTTTGATCCACCTGATGGCCAAGGCAGGCCTGACCCTGCAGCAG CAGCACCAGCGGCTGGCCCAGCTCCTCCTCATCCTCTCCCACATCAGGCACATGAGTAACAAAGGCATGGAGCATCTGTACAGCATGAAG TGCAAGAACGTGGTGCCCCTCTATGACCTGCTGCTGGAGATGCTGGACGCCCACCGCCTACATGCGCCCACTAGCCGTGGAGGGGCATCC GTGGAGGAGACGGACCAAAGCCACTTGGCCACTGCGGGCTCTACTTCATCGCATTCCTTGCAAAAGTATTACATCACGGGGGAGGCAGAG GGTTTCCCTGCCACGGTCTGAGAGCTCCCTGGCTCCCACACGGTTCAGATAATCCCTGCTGCATTTTACCCTCATCATGCACCACTTTAG CCAAATTCTGTCTCCTGCATACACTCCGGCATGCATCCAACACCAATGGCTTTCTAGATGAGTGGCCATTCATTTGCTTGCTCAGTTCTT AGTGGCACATCTTCTGTCTTCTGTTGGGAACAGCCAAAGGGATTCCAAGGCTAAATCTTTGTAACAGCTCTCTTTCCCCCTTGCTATGTT ACTAAGCGTGAGGATTCCCGTAGCTCTTCACAGCTGAACTCAGTCTATGGGTTGGGGCTCAGATAACTCTGTGCATTTAAGCTACTTGTA GAGACCCAGGCCTGGAGAGTAGACATTTTGCCTCTGATAAGCACTTTTTAAATGGCTCTAAGAATAAGCCACAGCAAAGAATTTAAAGTG GCTCCTTTAATTGGTGACTTGGAGAAAGCTAGGTCAAGGGTTTATTATAGCACCCTCTTGTATTCCTATGGCAATGCATCCTTTTATGAA AGTGGTACACCTTAAAGCTTTTATATGACTGTAGCAGAGTATCTGGTGATTGTCAATTCATTCCCCCTATAGGAATACAAGGGGCACACA GGGAAGGCAGATCCCCTAGTTGGCAAGACTATTTTAACTTGATACACTGCAGATTCAGATGTGCTGAAAGCTCTGCCTCTGGCTTTCCGG TCATGGGTTCCAGTTAATTCATGCCTCCCATGGACCTATGGAGAGCAGCAAGTTGATCTTAGTTAAGTCTCCCTATATGAGGGATAAGTT CCTGATTTTTGTTTTTATTTTTGTGTTACAAAAGAAAGCCCTCCCTCCCTGAACTTGCAGTAAGGTCAGCTTCAGGACCTGTTCCAGTGG GCACTGTACTTGGATCTTCCCGGCGTGTGTGTGCCTTACACAGGGGTGAACTGTTCACTGTGGTGATGCATGATGAGGGTAAATGGTAGT TGAAAGGAGCAGGGGCCCTGGTGTTGCATTTAGCCCTGGGGCATGGAGCTGAACAGTACTTGTGCAGGATTGTTGTGGCTACTAGAGAAC AAGAGGGAAAGTAGGGCAGAAACTGGATACAGTTCTGAGGCACAGCCAGACTTGCTCAGGGTGGCCCTGCCACAGGCTGCAGCTACCTAG GAACATTCCTTGCAGACCCCGCATTGCCCTTTGGGGGTGCCCTGGGATCCCTGGGGTAGTCCAGCTCTTCTTCATTTCCCAGCGTGGCCC TGGTTGGAAGAAGCAGCTGTCACAGCTGCTGTAGACAGCTGTGTTCCTACAATTGGCCCAGCACCCTGGGGCACGGGAGAAGGGTGGGGA CCGTTGCTGTCACTACTCAGGCTGACTGGGGCCTGGTCAGATTACGTATGCCCTTGGTGGTTTAGAGATAATCCAAAATCAGGGTTTGGT TTGGGGAAGAAAATCCTCCCCCTTCCTCCCCCGCCCCGTTCCCTACCGCCTCCACTCCTGCCAGCTCATTTCCTTCAATTTCCTTTGACC TATAGGCTAAAAAAGAAAGGCTCATTCCAGCCACAGGGCAGCCTTCCCTGGGCCTTTGCTTCTCTAGCACAATTATGGGTTACTTCCTTT TTCTTAACAAAAAAGAATGTTTGATTTCCTCTGGGTGACCTTATTGTCTGTAATTGAAACCCTATTGAGAGGTGATGTCTGTGTTAGCCA ATGACCCAGGTGAGCTGCTCGGGCTTCTCTTGGTATGTCTTGTTTGGAAAAGTGGATTTCATTCATTTCTGATTGTCCAGTTAAGTGATC ACCAAAGGACTGAGAATCTGGGAGGGCAAAAAAAAAAAAAAAGTTTTTATGTGCACTTAAATTTGGGGACAATTTTATGTATCTGTGTTA AGGATATGTTTAAGAACATAATTCTTTTGTTGCTGTTTGTTTAAGAAGCACCTTAGTTTGTTTAAGAAGCACCTTATATAGTATAATATA TATTTTTTTGAAATTACATTGCTTGTTTATCAGACAATTGAATGTAGTAATTCTGTTCTGGATTTAATTTGACTGGGTTAACATGCAAAA ACCAAGGAAAAATATTTAGTTTTTTTTTTTTTTTTTGTATACTTTTCAAGCTACCTTGTCATGTATACAGTCATTTATGCCTAAAGCCTG GTGATTATTCATTTAAATGAAGATCACATTTCATATCAACTTTTGTATCCACAGTAGACAAAATAGCACTAATCCAGATGCCTATTGTTG GATACTGAATGACAGACAATCTTATGTAGCAAAGATTATGCCTGAAAAGGAAAATTATTCAGGGCAGCTAATTTTGCTTTTACCAAAATA TCAGTAGTAATATTTTTGGACAGTAGCTAATGGGTCAGTGGGTTCTTTTTAATGTTTATACTTAGATTTTCTTTTAAAAAAATTAAAATA AAACAAAAAAAAATTTCTAGGACTAGACGATGTAATACCAGCTAAAGCCAAACAATTATACAGTGGAAGGTTTTACATTATTCATCCAAT GTGTTTCTATTCATGTTAAGATACTACTACATTTGAAGTGGGCAGAGAACATCAGATGATTGAAATGTTCGCCCAGGGGTCTCCAGCAAC TTTGGAAATCTCTTTGTATTTTTACTTGAAGTGCCACTAATGGACAGCAGATATTTTCTGGCTGATGTTGGTATTGGGTGTAGGAACATG ATTTAAAAAAAAACTCTTGCCTCTGCTTTCCCCCACTCTGAGGCAAGTTAAAATGTAAAAGATGTGATTTATCTGGGGGGCTCAGGTATG GTGGGGAAGTGGATTCAGGAATCTGGGGAATGGCAAATATATTAAGAAGAGTATTGAAAGTATTTGGAGGAAAATGGTTAATTCTGGGTG TGCACCAGGGTTCAGTAGAGTCCACTTCTGCCCTGGAGACCACAAATCAACTAGCTCCATTTACAGCCATTTCTAAAATGGCAGCTTCAG TTCTAGAGAAGAAAGAACAACATCAGCAGTAAAGTCCATGGAATAGCTAGTGGTCTGTGTTTCTTTTCGCCATTGCCTAGCTTGCCGTAA TGATTCTATAATGCCATCATGCAGCAATTATGAGAGGCTAGGTCATCCAAAGAGAAGACCCTATCAATGTAGGTTGCAAAATCTAACCCC TAAGGAAGTGCAGTCTTTGATTTGATTTCCCTAGTAACCTTGCAGATATGTTTAACCAAGCCATAGCCCATGCCTTTTGAGGGCTGAACA AATAAGGGACTTACTGATAATTTACTTTTGATCACATTAAGGTGTTCTCACCTTGAAATCTTATACACTGAAATGGCCATTGATTTAGGC CACTGGCTTAGAGTACTCCTTCCCCTGCATGACACTGATTACAAATACTTTCCTATTCATACTTTCCAATTATGAGATGGACTGTGGGTA CTGGGAGTGATCACTAACACCATAGTAATGTCTAATATTCACAGGCAGATCTGCTTGGGGAAGCTAGTTATGTGAAAGGCAAATAGAGTC ATACAGTAGCTCAAAAGGCAACCATAATTCTCTTTGGTGCAGGTCTTGGGAGCGTGATCTAGATTACACTGCACCATTCCCAAGTTAATC CCCTGAAAACTTACTCTCAACTGGAGCAAATGAACTTTGGTCCCAAATATCCATCTTTTCAGTAGCGTTAATTATGCTCTGTTTCCAACT GCATTTCCTTTCCAATTGAATTAAAGTGTGGCCTCGTTTTTAGTCATTTAAAATTGTTTTCTAAGTAATTGCTGCCTCTATTATGGCACT TCAATTTTGCACTGTCTTTTGAGATTCAAGAAAAATTTCTATTCTTTTTTTTGCATCCAATTGTGCCTGAACTTTTAAAATATGTAAATG CTGCCATGTTCCAAACCCATCGTCAGTGTGTGTGTTTAGAGCTGTGCACCCTAGAAACAACATATTGTCCCATGAGCAGGTGCCTGAGAC ACAGACCCCTTTGCATTCACAGAGAGGTCATTGGTTATAGAGACTTGAATTAATAAGTGACATTATGCCAGTTTCTGTTCTCTCACAGGT GATAAACAATGCTTTTTGTGCACTACATACTCTTCAGTGTAGAGCTCTTGTTTTATGGGAAAAGGCTCAAATGCCAAATTGTGTTTGATG GATTAATATGCCCTTTTGCCGATGCATACTATTACTGATGTGACTCGGTTTTGTCGCAGCTTTGCTTTGTTTAATGAAACACACTTGTAA ACCTCTTTTGCACTTTGAAAAAGAATCCAGCGGGATGCTCGAGCACCTGTAAACAATTTTCTCAACCTATTTGATGTTCAAATAAAGAAT >In-frame_ENST00000404338_ENST00000440973_TCGA-A8-A06O_ARHGAP35_chr19_47440665_+_ESR1_chr6_152201789_length(amino acids)=1656AA_start in transcript=0_stop in transcript=4970 MMMARKQDVRIPTYNISVVGLSGTEKEKGQCGIGKSCLCNRFVRPSADEFHLDHTSVLSTSDFGGRVVNNDHFLYWGEVSRSLEDCVECK MHIVEQTEFIDDQTFQPHRSTALQPYIKRAAATKLASAEKLMYFCTDQLGLEQDFEQKQMPDGKLLVDGFLLGIDVSRGMNRNFDDQLKF VSNLYNQLAKTKKPIVVVLTKCDEGVERYIRDAHTFALSKKNLQVVETSARSNVNVDLAFSTLVQLIDKSRGKTKIIPYFEALKQQSQQI ATAKDKYEWLVSRIVKNHNENWLSVSRKMQASPEYQDYVYLEGTQKAKKLFLQHIHRLKHEHIERRRKLYLAALPLAFEALIPNLDEIDH LSCIKAKKLLETKPEFLKWFVVLEETPWDATSHIDNMENERIPFDLMDTVPAEQLYEAHLEKLRNERKRVEMRRAFKENLETSPFITPGK PWEEARSFIMNEDFYQWLEESVYMDIYGKHQKQIIDKAKEEFQELLLEYSELFYELELDAKPSKEKMGVIQDVLGEEQRFKALQKLQAER DALILKHIHFVYHPTKETCPSCPACVDAKIEHLISSRFIRPSDRNQKNSLSDPNIDRINLVILGKDGLARELANEIRALCTNDDKYVIDG KMYELSLRPIEGNVRLPVNSFQTPTFQPHGCLCLYNSKESLSYVVESIEKSRESTLGRRDNHLVHLPLTLILVNKRGDTSGETLHSLIQQ GQQIASKLQCVFLDPASAGIGYGRNINEKQISQVLKGLLDSKRNLNLVSSTASIKDLADVDLRIVMCLMCGDPFSADDILFPVLQSQTCK SSHCGSNNSVLLELPIGLHKKRIELSVLSYHSSFSIRKSRLVHGYIVFYSAKRKASLAMLRAFLCEVQDIIPIQLVALTDGAVDVLDNDL SREQLTEGEEIAQEIDGRFTSIPCSQPQHKLEIFHPFFKDVVEKKNIIEATHMYDNAAEACSTTEEVFNSPRAGSPLCNSNLQDSEEDIE PSYSLFREDTSLPSLSKDHSKLSMELEGNDGLSFIMSNFESKLNNKVPPPVKPKPPVHFEITKGDLSYLDQGHRDGQRKSVSSSPWLPQD GFDPSDYAEPMDAVVKPRNEEENIYSVPHDSTQGKIITIRNINKAQSNGSGNGSDSEMDTSSLERGRKVSIVSKPVLYRTRCTRLGRFAS YRTSFSVGSDDELGPIRKKEEDQASQGYKGDNAVIPYETDEDPRRRNILRSLRRNTKKPKPKPRPSITKATWESNYFGVPLTTVVTPEKP IPIFIERCIEYIEATGHNDYMCPATNQCTIDKNRRKSCQACRLRKCYEVGMMKGGIRKDRRGGRMLKHKRQRDDGEGRGEVGSAGDMRAA NLWPSPLMIKRSKKNSLALSLTADQMVSALLDAEPPILYSEYDPTRPFSEASMMGLLTNLADRELVHMINWAKRVPGFVDLTLHDQVHLL ECAWLEILMIGLVWRSMEHPGKLLFAPNLLLDRNQGKCVEGMVEIFDMLLATSSRFRMMNLQGEEFVCLKSIILLNSGVYTFLSSTLKSL EEKDHIHRVLDKITDTLIHLMAKAGLTLQQQHQRLAQLLLILSHIRHMSNKGMEHLYSMKCKNVVPLYDLLLEMLDAHRLHAPTSRGGAS -------------------------------------------------------------- >In-frame_ENST00000404338_ENST00000338799_TCGA-A8-A06O_ARHGAP35_chr19_47440665_+_ESR1_chr6_152201789_length(transcript)=5058nt_BP=3826nt ATGATGATGGCAAGAAAGCAAGATGTCCGAATTCCCACCTACAACATCAGTGTGGTGGGATTATCTGGGACCGAGAAGGAAAAGGGCCAG TGTGGGATTGGAAAGTCTTGTTTGTGCAACCGCTTCGTGCGCCCGAGTGCTGACGAGTTTCACTTGGACCATACCTCCGTCCTCAGCACC AGTGACTTTGGAGGGCGAGTGGTCAATAATGACCACTTTCTCTACTGGGGAGAAGTTAGCCGCTCCCTGGAGGATTGTGTGGAATGTAAG ATGCACATTGTGGAGCAGACTGAATTTATTGATGATCAGACTTTTCAACCTCATCGAAGCACGGCCCTGCAGCCCTATATCAAGAGAGCT GCTGCGACCAAGCTTGCATCAGCTGAAAAACTCATGTACTTTTGCACTGACCAGCTGGGGCTGGAGCAGGACTTTGAGCAGAAACAAATG CCAGACGGAAAGCTGCTGGTTGATGGTTTTCTTCTTGGTATTGATGTTAGCAGGGGCATGAATAGGAACTTTGATGACCAGCTCAAGTTT GTCTCCAATCTCTACAATCAGCTTGCAAAAACAAAAAAGCCCATAGTGGTGGTCCTGACTAAGTGTGACGAAGGTGTTGAGCGGTACATT AGAGATGCACATACTTTTGCCTTAAGCAAAAAGAACCTCCAGGTTGTGGAGACCTCAGCGAGATCCAATGTAAACGTGGACTTGGCTTTC AGCACCTTAGTGCAACTCATTGATAAAAGTCGGGGAAAGACAAAAATCATTCCTTATTTTGAAGCTCTCAAGCAGCAGAGTCAGCAGATA GCTACAGCAAAAGACAAGTATGAGTGGCTGGTGAGTCGCATTGTGAAAAACCACAATGAGAACTGGCTGAGTGTCAGCCGAAAGATGCAG GCCTCTCCAGAATACCAGGACTATGTCTACCTGGAAGGGACTCAGAAAGCCAAGAAGCTGTTTCTACAGCACATCCACCGCCTCAAGCAT GAGCATATCGAGCGTAGGAGAAAGCTGTACCTGGCAGCCCTGCCATTAGCTTTTGAAGCTCTTATACCTAATCTAGATGAAATAGACCAC CTAAGCTGCATAAAAGCCAAAAAGCTCTTAGAAACCAAGCCAGAATTCTTGAAGTGGTTTGTTGTGCTTGAAGAGACCCCATGGGATGCC ACCAGTCACATTGACAACATGGAAAACGAACGGATTCCCTTTGATTTAATGGATACCGTCCCTGCAGAGCAGCTATACGAGGCCCACTTA GAGAAGCTGAGGAACGAAAGGAAAAGAGTTGAGATGCGAAGGGCGTTTAAAGAAAACCTGGAGACTTCTCCTTTCATAACTCCCGGAAAG CCTTGGGAAGAGGCCCGTAGTTTTATTATGAATGAGGATTTCTACCAGTGGCTGGAGGAATCTGTATACATGGATATTTATGGCAAACAC CAAAAGCAAATTATAGATAAAGCAAAGGAAGAATTTCAGGAGTTGCTTTTGGAATATTCAGAATTGTTTTATGAACTGGAGCTGGATGCT AAGCCCAGCAAGGAGAAGATGGGTGTTATTCAGGATGTTCTGGGAGAGGAACAGCGATTTAAAGCATTACAAAAGCTCCAAGCAGAGCGT GATGCCCTTATTCTGAAACACATTCATTTTGTGTACCACCCAACAAAGGAGACATGCCCCAGCTGCCCAGCTTGTGTGGACGCTAAGATT GAGCACTTGATTAGTTCTCGGTTTATCCGGCCGTCTGACCGGAATCAGAAAAATTCACTCTCTGACCCTAACATTGATAGAATCAACTTG GTTATATTGGGCAAAGACGGCCTTGCCCGAGAGTTGGCCAATGAGATTCGAGCTCTTTGTACAAATGATGACAAGTATGTGATAGATGGT AAAATGTATGAGCTTTCCCTGAGGCCAATAGAGGGGAATGTCAGGCTTCCTGTGAACTCTTTCCAGACGCCAACATTTCAGCCCCACGGC TGTCTCTGCCTTTACAATTCAAAGGAATCGCTATCCTATGTAGTGGAAAGTATAGAGAAGAGTAGAGAGTCCACGCTGGGCCGGCGGGAT AATCATTTAGTCCATCTCCCCCTTACATTAATTTTGGTTAACAAGAGAGGAGACACCAGTGGAGAGACTCTGCATAGCTTAATACAGCAA GGTCAACAAATTGCTAGCAAACTTCAGTGTGTCTTTCTCGACCCTGCTTCTGCTGGCATTGGTTACGGACGCAACATTAATGAAAAGCAA ATCAGTCAAGTTTTGAAGGGACTCCTGGACTCTAAGCGTAACTTAAACCTGGTCAGTTCTACTGCTAGCATCAAAGATTTGGCTGATGTT GATCTGCGAATTGTTATGTGTCTGATGTGTGGAGATCCTTTTAGTGCAGATGACATACTTTTTCCTGTCCTTCAGTCCCAAACCTGTAAA TCTTCCCATTGTGGAAGCAACAACTCTGTTTTACTTGAACTACCAATCGGACTGCACAAGAAGCGGATTGAACTGTCTGTTCTTTCATAC CATTCCTCCTTTAGCATCAGAAAGAGCCGGTTGGTTCATGGGTACATTGTTTTTTATTCAGCCAAACGTAAGGCCTCTTTGGCTATGTTA CGTGCCTTTCTTTGTGAAGTGCAGGATATTATCCCTATTCAGCTTGTAGCACTCACTGATGGCGCTGTAGATGTCCTGGACAATGACTTA AGTAGGGAACAGCTAACTGAGGGGGAGGAGATTGCTCAAGAAATTGACGGAAGGTTCACAAGCATCCCCTGTAGCCAACCCCAGCATAAA CTTGAGATCTTTCACCCATTTTTTAAAGATGTGGTGGAAAAAAAGAACATAATCGAGGCTACTCATATGTACGATAATGCTGCCGAGGCC TGTAGCACCACCGAAGAGGTGTTTAACTCCCCCCGGGCAGGATCACCGCTCTGCAACTCAAACCTGCAGGATTCAGAAGAAGATATCGAG CCATCTTACAGCCTGTTTCGAGAAGACACATCACTGCCTTCTCTGTCCAAAGACCATTCTAAGCTCTCTATGGAACTGGAGGGAAATGAT GGGCTGTCTTTCATTATGAGCAATTTTGAGAGTAAACTGAACAACAAAGTACCTCCGCCAGTCAAACCAAAGCCTCCTGTCCATTTTGAA ATTACAAAGGGGGATCTATCTTATTTAGACCAAGGCCATAGGGATGGACAGAGGAAGTCTGTGTCTTCTAGCCCCTGGCTGCCTCAGGAT GGGTTTGATCCTTCTGACTATGCTGAACCCATGGATGCTGTGGTGAAGCCAAGGAATGAAGAAGAAAACATATACTCCGTGCCCCATGAC AGCACCCAAGGCAAAATCATCACCATTCGGAATATCAACAAAGCCCAGTCCAACGGCAGCGGGAATGGTTCTGACAGTGAAATGGACACC AGCTCTCTAGAGCGAGGGCGCAAGGTTTCCATCGTGAGCAAGCCAGTGCTGTACAGGACGAGATGCACCCGGCTGGGGCGGTTTGCTAGT TACCGGACCAGCTTCAGCGTGGGGAGTGATGATGAGCTGGGGCCCATCCGGAAGAAAGAGGAGGATCAGGCATCCCAGGGTTATAAAGGG GACAATGCTGTCATTCCATACGAAACAGACGAAGACCCGCGGAGGAGGAATATTCTTCGCAGCCTAAGGAGGAACACTAAGAAACCAAAG CCCAAACCCCGGCCATCCATCACAAAGGCAACCTGGGAGAGTAACTATTTTGGGGTGCCCTTAACAACTGTCGTGACTCCAGAGAAGCCG ATCCCCATTTTTATTGAAAGATGTATTGAGTACATTGAAGCCACAGGACATAACGACTATATGTGTCCAGCCACCAACCAGTGCACCATT GATAAAAACAGGAGGAAGAGCTGCCAGGCCTGCCGGCTCCGTAAATGCTACGAAGTGGGAATGATGAAAGGTGGGATACGAAAAGACCGA AGAGGAGGGAGAATGTTGAAACACAAGCGCCAGAGAGATGATGGGGAGGGCAGGGGTGAAGTGGGGTCTGCTGGAGACATGAGAGCTGCC AACCTTTGGCCAAGCCCGCTCATGATCAAACGCTCTAAGAAGAACAGCCTGGCCTTGTCCCTGACGGCCGACCAGATGGTCAGTGCCTTG TTGGATGCTGAGCCCCCGATACTCTATTCCGAGTATGATCCTACCAGACCCTTCAGTGAAGCTTCGATGATGGGCTTACTGACCAACCTG GCAGACAGGGAGCTGGTTCACATGATCAACTGGGCGAAGAGGGTGCCAGGCTTTGTGGATTTGACCCTCCATGATCAGGTCCACCTTCTA GAATGTGCCTGGCTAGAGATCCTGATGATTGGTCTCGTCTGGCGCTCCATGGAGCACCCAGGGAAGCTACTGTTTGCTCCTAACTTGCTC TTGGACAGGAACCAGGGAAAATGTGTAGAGGGCATGGTGGAGATCTTCGACATGCTGCTGGCTACATCATCTCGGTTCCGCATGATGAAT CTGCAGGGAGAGGAGTTTGTGTGCCTCAAATCTATTATTTTGCTTAATTCTGGAGTGTACACATTTCTGTCCAGCACCCTGAAGTCTCTG GAAGAGAAGGACCATATCCACCGAGTCCTGGACAAGATCACAGACACTTTGATCCACCTGATGGCCAAGGCAGGCCTGACCCTGCAGCAG CAGCACCAGCGGCTGGCCCAGCTCCTCCTCATCCTCTCCCACATCAGGCACATGAGTAACAAAGGCATGGAGCATCTGTACAGCATGAAG TGCAAGAACGTGGTGCCCCTCTATGACCTGCTGCTGGAGATGCTGGACGCCCACCGCCTACATGCGCCCACTAGCCGTGGAGGGGCATCC GTGGAGGAGACGGACCAAAGCCACTTGGCCACTGCGGGCTCTACTTCATCGCATTCCTTGCAAAAGTATTACATCACGGGGGAGGCAGAG GGTTTCCCTGCCACGGTCTGAGAGCTCCCTGGCTCCCACACGGTTCAGATAATCCCTGCTGCATTTTACCCTCATCATGCACCACTTTAG >In-frame_ENST00000404338_ENST00000338799_TCGA-A8-A06O_ARHGAP35_chr19_47440665_+_ESR1_chr6_152201789_length(amino acids)=1656AA_start in transcript=0_stop in transcript=4970 MMMARKQDVRIPTYNISVVGLSGTEKEKGQCGIGKSCLCNRFVRPSADEFHLDHTSVLSTSDFGGRVVNNDHFLYWGEVSRSLEDCVECK MHIVEQTEFIDDQTFQPHRSTALQPYIKRAAATKLASAEKLMYFCTDQLGLEQDFEQKQMPDGKLLVDGFLLGIDVSRGMNRNFDDQLKF VSNLYNQLAKTKKPIVVVLTKCDEGVERYIRDAHTFALSKKNLQVVETSARSNVNVDLAFSTLVQLIDKSRGKTKIIPYFEALKQQSQQI ATAKDKYEWLVSRIVKNHNENWLSVSRKMQASPEYQDYVYLEGTQKAKKLFLQHIHRLKHEHIERRRKLYLAALPLAFEALIPNLDEIDH LSCIKAKKLLETKPEFLKWFVVLEETPWDATSHIDNMENERIPFDLMDTVPAEQLYEAHLEKLRNERKRVEMRRAFKENLETSPFITPGK PWEEARSFIMNEDFYQWLEESVYMDIYGKHQKQIIDKAKEEFQELLLEYSELFYELELDAKPSKEKMGVIQDVLGEEQRFKALQKLQAER DALILKHIHFVYHPTKETCPSCPACVDAKIEHLISSRFIRPSDRNQKNSLSDPNIDRINLVILGKDGLARELANEIRALCTNDDKYVIDG KMYELSLRPIEGNVRLPVNSFQTPTFQPHGCLCLYNSKESLSYVVESIEKSRESTLGRRDNHLVHLPLTLILVNKRGDTSGETLHSLIQQ GQQIASKLQCVFLDPASAGIGYGRNINEKQISQVLKGLLDSKRNLNLVSSTASIKDLADVDLRIVMCLMCGDPFSADDILFPVLQSQTCK SSHCGSNNSVLLELPIGLHKKRIELSVLSYHSSFSIRKSRLVHGYIVFYSAKRKASLAMLRAFLCEVQDIIPIQLVALTDGAVDVLDNDL SREQLTEGEEIAQEIDGRFTSIPCSQPQHKLEIFHPFFKDVVEKKNIIEATHMYDNAAEACSTTEEVFNSPRAGSPLCNSNLQDSEEDIE PSYSLFREDTSLPSLSKDHSKLSMELEGNDGLSFIMSNFESKLNNKVPPPVKPKPPVHFEITKGDLSYLDQGHRDGQRKSVSSSPWLPQD GFDPSDYAEPMDAVVKPRNEEENIYSVPHDSTQGKIITIRNINKAQSNGSGNGSDSEMDTSSLERGRKVSIVSKPVLYRTRCTRLGRFAS YRTSFSVGSDDELGPIRKKEEDQASQGYKGDNAVIPYETDEDPRRRNILRSLRRNTKKPKPKPRPSITKATWESNYFGVPLTTVVTPEKP IPIFIERCIEYIEATGHNDYMCPATNQCTIDKNRRKSCQACRLRKCYEVGMMKGGIRKDRRGGRMLKHKRQRDDGEGRGEVGSAGDMRAA NLWPSPLMIKRSKKNSLALSLTADQMVSALLDAEPPILYSEYDPTRPFSEASMMGLLTNLADRELVHMINWAKRVPGFVDLTLHDQVHLL ECAWLEILMIGLVWRSMEHPGKLLFAPNLLLDRNQGKCVEGMVEIFDMLLATSSRFRMMNLQGEEFVCLKSIILLNSGVYTFLSSTLKSL EEKDHIHRVLDKITDTLIHLMAKAGLTLQQQHQRLAQLLLILSHIRHMSNKGMEHLYSMKCKNVVPLYDLLLEMLDAHRLHAPTSRGGAS -------------------------------------------------------------- >In-frame_ENST00000404338_ENST00000456483_TCGA-A8-A06O_ARHGAP35_chr19_47440665_+_ESR1_chr6_152201789_length(transcript)=8943nt_BP=3826nt ATGATGATGGCAAGAAAGCAAGATGTCCGAATTCCCACCTACAACATCAGTGTGGTGGGATTATCTGGGACCGAGAAGGAAAAGGGCCAG TGTGGGATTGGAAAGTCTTGTTTGTGCAACCGCTTCGTGCGCCCGAGTGCTGACGAGTTTCACTTGGACCATACCTCCGTCCTCAGCACC AGTGACTTTGGAGGGCGAGTGGTCAATAATGACCACTTTCTCTACTGGGGAGAAGTTAGCCGCTCCCTGGAGGATTGTGTGGAATGTAAG ATGCACATTGTGGAGCAGACTGAATTTATTGATGATCAGACTTTTCAACCTCATCGAAGCACGGCCCTGCAGCCCTATATCAAGAGAGCT GCTGCGACCAAGCTTGCATCAGCTGAAAAACTCATGTACTTTTGCACTGACCAGCTGGGGCTGGAGCAGGACTTTGAGCAGAAACAAATG CCAGACGGAAAGCTGCTGGTTGATGGTTTTCTTCTTGGTATTGATGTTAGCAGGGGCATGAATAGGAACTTTGATGACCAGCTCAAGTTT GTCTCCAATCTCTACAATCAGCTTGCAAAAACAAAAAAGCCCATAGTGGTGGTCCTGACTAAGTGTGACGAAGGTGTTGAGCGGTACATT AGAGATGCACATACTTTTGCCTTAAGCAAAAAGAACCTCCAGGTTGTGGAGACCTCAGCGAGATCCAATGTAAACGTGGACTTGGCTTTC AGCACCTTAGTGCAACTCATTGATAAAAGTCGGGGAAAGACAAAAATCATTCCTTATTTTGAAGCTCTCAAGCAGCAGAGTCAGCAGATA GCTACAGCAAAAGACAAGTATGAGTGGCTGGTGAGTCGCATTGTGAAAAACCACAATGAGAACTGGCTGAGTGTCAGCCGAAAGATGCAG GCCTCTCCAGAATACCAGGACTATGTCTACCTGGAAGGGACTCAGAAAGCCAAGAAGCTGTTTCTACAGCACATCCACCGCCTCAAGCAT GAGCATATCGAGCGTAGGAGAAAGCTGTACCTGGCAGCCCTGCCATTAGCTTTTGAAGCTCTTATACCTAATCTAGATGAAATAGACCAC CTAAGCTGCATAAAAGCCAAAAAGCTCTTAGAAACCAAGCCAGAATTCTTGAAGTGGTTTGTTGTGCTTGAAGAGACCCCATGGGATGCC ACCAGTCACATTGACAACATGGAAAACGAACGGATTCCCTTTGATTTAATGGATACCGTCCCTGCAGAGCAGCTATACGAGGCCCACTTA GAGAAGCTGAGGAACGAAAGGAAAAGAGTTGAGATGCGAAGGGCGTTTAAAGAAAACCTGGAGACTTCTCCTTTCATAACTCCCGGAAAG CCTTGGGAAGAGGCCCGTAGTTTTATTATGAATGAGGATTTCTACCAGTGGCTGGAGGAATCTGTATACATGGATATTTATGGCAAACAC CAAAAGCAAATTATAGATAAAGCAAAGGAAGAATTTCAGGAGTTGCTTTTGGAATATTCAGAATTGTTTTATGAACTGGAGCTGGATGCT AAGCCCAGCAAGGAGAAGATGGGTGTTATTCAGGATGTTCTGGGAGAGGAACAGCGATTTAAAGCATTACAAAAGCTCCAAGCAGAGCGT GATGCCCTTATTCTGAAACACATTCATTTTGTGTACCACCCAACAAAGGAGACATGCCCCAGCTGCCCAGCTTGTGTGGACGCTAAGATT GAGCACTTGATTAGTTCTCGGTTTATCCGGCCGTCTGACCGGAATCAGAAAAATTCACTCTCTGACCCTAACATTGATAGAATCAACTTG GTTATATTGGGCAAAGACGGCCTTGCCCGAGAGTTGGCCAATGAGATTCGAGCTCTTTGTACAAATGATGACAAGTATGTGATAGATGGT AAAATGTATGAGCTTTCCCTGAGGCCAATAGAGGGGAATGTCAGGCTTCCTGTGAACTCTTTCCAGACGCCAACATTTCAGCCCCACGGC TGTCTCTGCCTTTACAATTCAAAGGAATCGCTATCCTATGTAGTGGAAAGTATAGAGAAGAGTAGAGAGTCCACGCTGGGCCGGCGGGAT AATCATTTAGTCCATCTCCCCCTTACATTAATTTTGGTTAACAAGAGAGGAGACACCAGTGGAGAGACTCTGCATAGCTTAATACAGCAA GGTCAACAAATTGCTAGCAAACTTCAGTGTGTCTTTCTCGACCCTGCTTCTGCTGGCATTGGTTACGGACGCAACATTAATGAAAAGCAA ATCAGTCAAGTTTTGAAGGGACTCCTGGACTCTAAGCGTAACTTAAACCTGGTCAGTTCTACTGCTAGCATCAAAGATTTGGCTGATGTT GATCTGCGAATTGTTATGTGTCTGATGTGTGGAGATCCTTTTAGTGCAGATGACATACTTTTTCCTGTCCTTCAGTCCCAAACCTGTAAA TCTTCCCATTGTGGAAGCAACAACTCTGTTTTACTTGAACTACCAATCGGACTGCACAAGAAGCGGATTGAACTGTCTGTTCTTTCATAC CATTCCTCCTTTAGCATCAGAAAGAGCCGGTTGGTTCATGGGTACATTGTTTTTTATTCAGCCAAACGTAAGGCCTCTTTGGCTATGTTA CGTGCCTTTCTTTGTGAAGTGCAGGATATTATCCCTATTCAGCTTGTAGCACTCACTGATGGCGCTGTAGATGTCCTGGACAATGACTTA AGTAGGGAACAGCTAACTGAGGGGGAGGAGATTGCTCAAGAAATTGACGGAAGGTTCACAAGCATCCCCTGTAGCCAACCCCAGCATAAA CTTGAGATCTTTCACCCATTTTTTAAAGATGTGGTGGAAAAAAAGAACATAATCGAGGCTACTCATATGTACGATAATGCTGCCGAGGCC TGTAGCACCACCGAAGAGGTGTTTAACTCCCCCCGGGCAGGATCACCGCTCTGCAACTCAAACCTGCAGGATTCAGAAGAAGATATCGAG CCATCTTACAGCCTGTTTCGAGAAGACACATCACTGCCTTCTCTGTCCAAAGACCATTCTAAGCTCTCTATGGAACTGGAGGGAAATGAT GGGCTGTCTTTCATTATGAGCAATTTTGAGAGTAAACTGAACAACAAAGTACCTCCGCCAGTCAAACCAAAGCCTCCTGTCCATTTTGAA ATTACAAAGGGGGATCTATCTTATTTAGACCAAGGCCATAGGGATGGACAGAGGAAGTCTGTGTCTTCTAGCCCCTGGCTGCCTCAGGAT GGGTTTGATCCTTCTGACTATGCTGAACCCATGGATGCTGTGGTGAAGCCAAGGAATGAAGAAGAAAACATATACTCCGTGCCCCATGAC AGCACCCAAGGCAAAATCATCACCATTCGGAATATCAACAAAGCCCAGTCCAACGGCAGCGGGAATGGTTCTGACAGTGAAATGGACACC AGCTCTCTAGAGCGAGGGCGCAAGGTTTCCATCGTGAGCAAGCCAGTGCTGTACAGGACGAGATGCACCCGGCTGGGGCGGTTTGCTAGT TACCGGACCAGCTTCAGCGTGGGGAGTGATGATGAGCTGGGGCCCATCCGGAAGAAAGAGGAGGATCAGGCATCCCAGGGTTATAAAGGG GACAATGCTGTCATTCCATACGAAACAGACGAAGACCCGCGGAGGAGGAATATTCTTCGCAGCCTAAGGAGGAACACTAAGAAACCAAAG CCCAAACCCCGGCCATCCATCACAAAGGCAACCTGGGAGAGTAACTATTTTGGGGTGCCCTTAACAACTGTCGTGACTCCAGAGAAGCCG ATCCCCATTTTTATTGAAAGATGTATTGAGTACATTGAAGCCACAGGACATAACGACTATATGTGTCCAGCCACCAACCAGTGCACCATT GATAAAAACAGGAGGAAGAGCTGCCAGGCCTGCCGGCTCCGTAAATGCTACGAAGTGGGAATGATGAAAGGTGGCTTTGTGGATTTGACC CTCCATGATCAGGTCCACCTTCTAGAATGTGCCTGGCTAGAGATCCTGATGATTGGTCTCGTCTGGCGCTCCATGGAGCACCCAGGGAAG CTACTGTTTGCTCCTAACTTGCTCTTGGACAGGAACCAGGGAAAATGTGTAGAGGGCATGGTGGAGATCTTCGACATGCTGCTGGCTACA TCATCTCGGTTCCGCATGATGAATCTGCAGGGAGAGGAGTTTGTGTGCCTCAAATCTATTATTTTGCTTAATTCTGGAGTGTACACATTT CTGTCCAGCACCCTGAAGTCTCTGGAAGAGAAGGACCATATCCACCGAGTCCTGGACAAGATCACAGACACTTTGATCCACCTGATGGCC AAGGCAGGCCTGACCCTGCAGCAGCAGCACCAGCGGCTGGCCCAGCTCCTCCTCATCCTCTCCCACATCAGGCACATGAGTAACAAAGGC ATGGAGCATCTGTACAGCATGAAGTGCAAGAACGTGGTGCCCCTCTATGACCTGCTGCTGGAGATGCTGGACGCCCACCGCCTACATGCG CCCACTAGCCGTGGAGGGGCATCCGTGGAGGAGACGGACCAAAGCCACTTGGCCACTGCGGGCTCTACTTCATCGCATTCCTTGCAAAAG TATTACATCACGGGGGAGGCAGAGGGTTTCCCTGCCACGGTCTGAGAGCTCCCTGGCTCCCACACGGTTCAGATAATCCCTGCTGCATTT TACCCTCATCATGCACCACTTTAGCCAAATTCTGTCTCCTGCATACACTCCGGCATGCATCCAACACCAATGGCTTTCTAGATGAGTGGC CATTCATTTGCTTGCTCAGTTCTTAGTGGCACATCTTCTGTCTTCTGTTGGGAACAGCCAAAGGGATTCCAAGGCTAAATCTTTGTAACA GCTCTCTTTCCCCCTTGCTATGTTACTAAGCGTGAGGATTCCCGTAGCTCTTCACAGCTGAACTCAGTCTATGGGTTGGGGCTCAGATAA CTCTGTGCATTTAAGCTACTTGTAGAGACCCAGGCCTGGAGAGTAGACATTTTGCCTCTGATAAGCACTTTTTAAATGGCTCTAAGAATA AGCCACAGCAAAGAATTTAAAGTGGCTCCTTTAATTGGTGACTTGGAGAAAGCTAGGTCAAGGGTTTATTATAGCACCCTCTTGTATTCC TATGGCAATGCATCCTTTTATGAAAGTGGTACACCTTAAAGCTTTTATATGACTGTAGCAGAGTATCTGGTGATTGTCAATTCATTCCCC CTATAGGAATACAAGGGGCACACAGGGAAGGCAGATCCCCTAGTTGGCAAGACTATTTTAACTTGATACACTGCAGATTCAGATGTGCTG AAAGCTCTGCCTCTGGCTTTCCGGTCATGGGTTCCAGTTAATTCATGCCTCCCATGGACCTATGGAGAGCAGCAAGTTGATCTTAGTTAA GTCTCCCTATATGAGGGATAAGTTCCTGATTTTTGTTTTTATTTTTGTGTTACAAAAGAAAGCCCTCCCTCCCTGAACTTGCAGTAAGGT CAGCTTCAGGACCTGTTCCAGTGGGCACTGTACTTGGATCTTCCCGGCGTGTGTGTGCCTTACACAGGGGTGAACTGTTCACTGTGGTGA TGCATGATGAGGGTAAATGGTAGTTGAAAGGAGCAGGGGCCCTGGTGTTGCATTTAGCCCTGGGGCATGGAGCTGAACAGTACTTGTGCA GGATTGTTGTGGCTACTAGAGAACAAGAGGGAAAGTAGGGCAGAAACTGGATACAGTTCTGAGGCACAGCCAGACTTGCTCAGGGTGGCC CTGCCACAGGCTGCAGCTACCTAGGAACATTCCTTGCAGACCCCGCATTGCCCTTTGGGGGTGCCCTGGGATCCCTGGGGTAGTCCAGCT CTTCTTCATTTCCCAGCGTGGCCCTGGTTGGAAGAAGCAGCTGTCACAGCTGCTGTAGACAGCTGTGTTCCTACAATTGGCCCAGCACCC TGGGGCACGGGAGAAGGGTGGGGACCGTTGCTGTCACTACTCAGGCTGACTGGGGCCTGGTCAGATTACGTATGCCCTTGGTGGTTTAGA GATAATCCAAAATCAGGGTTTGGTTTGGGGAAGAAAATCCTCCCCCTTCCTCCCCCGCCCCGTTCCCTACCGCCTCCACTCCTGCCAGCT CATTTCCTTCAATTTCCTTTGACCTATAGGCTAAAAAAGAAAGGCTCATTCCAGCCACAGGGCAGCCTTCCCTGGGCCTTTGCTTCTCTA GCACAATTATGGGTTACTTCCTTTTTCTTAACAAAAAAGAATGTTTGATTTCCTCTGGGTGACCTTATTGTCTGTAATTGAAACCCTATT GAGAGGTGATGTCTGTGTTAGCCAATGACCCAGGTGAGCTGCTCGGGCTTCTCTTGGTATGTCTTGTTTGGAAAAGTGGATTTCATTCAT TTCTGATTGTCCAGTTAAGTGATCACCAAAGGACTGAGAATCTGGGAGGGCAAAAAAAAAAAAAAAGTTTTTATGTGCACTTAAATTTGG GGACAATTTTATGTATCTGTGTTAAGGATATGTTTAAGAACATAATTCTTTTGTTGCTGTTTGTTTAAGAAGCACCTTAGTTTGTTTAAG AAGCACCTTATATAGTATAATATATATTTTTTTGAAATTACATTGCTTGTTTATCAGACAATTGAATGTAGTAATTCTGTTCTGGATTTA ATTTGACTGGGTTAACATGCAAAAACCAAGGAAAAATATTTAGTTTTTTTTTTTTTTTTTGTATACTTTTCAAGCTACCTTGTCATGTAT ACAGTCATTTATGCCTAAAGCCTGGTGATTATTCATTTAAATGAAGATCACATTTCATATCAACTTTTGTATCCACAGTAGACAAAATAG CACTAATCCAGATGCCTATTGTTGGATACTGAATGACAGACAATCTTATGTAGCAAAGATTATGCCTGAAAAGGAAAATTATTCAGGGCA GCTAATTTTGCTTTTACCAAAATATCAGTAGTAATATTTTTGGACAGTAGCTAATGGGTCAGTGGGTTCTTTTTAATGTTTATACTTAGA TTTTCTTTTAAAAAAATTAAAATAAAACAAAAAAAAATTTCTAGGACTAGACGATGTAATACCAGCTAAAGCCAAACAATTATACAGTGG AAGGTTTTACATTATTCATCCAATGTGTTTCTATTCATGTTAAGATACTACTACATTTGAAGTGGGCAGAGAACATCAGATGATTGAAAT GTTCGCCCAGGGGTCTCCAGCAACTTTGGAAATCTCTTTGTATTTTTACTTGAAGTGCCACTAATGGACAGCAGATATTTTCTGGCTGAT GTTGGTATTGGGTGTAGGAACATGATTTAAAAAAAAACTCTTGCCTCTGCTTTCCCCCACTCTGAGGCAAGTTAAAATGTAAAAGATGTG ATTTATCTGGGGGGCTCAGGTATGGTGGGGAAGTGGATTCAGGAATCTGGGGAATGGCAAATATATTAAGAAGAGTATTGAAAGTATTTG GAGGAAAATGGTTAATTCTGGGTGTGCACCAGGGTTCAGTAGAGTCCACTTCTGCCCTGGAGACCACAAATCAACTAGCTCCATTTACAG CCATTTCTAAAATGGCAGCTTCAGTTCTAGAGAAGAAAGAACAACATCAGCAGTAAAGTCCATGGAATAGCTAGTGGTCTGTGTTTCTTT TCGCCATTGCCTAGCTTGCCGTAATGATTCTATAATGCCATCATGCAGCAATTATGAGAGGCTAGGTCATCCAAAGAGAAGACCCTATCA ATGTAGGTTGCAAAATCTAACCCCTAAGGAAGTGCAGTCTTTGATTTGATTTCCCTAGTAACCTTGCAGATATGTTTAACCAAGCCATAG CCCATGCCTTTTGAGGGCTGAACAAATAAGGGACTTACTGATAATTTACTTTTGATCACATTAAGGTGTTCTCACCTTGAAATCTTATAC ACTGAAATGGCCATTGATTTAGGCCACTGGCTTAGAGTACTCCTTCCCCTGCATGACACTGATTACAAATACTTTCCTATTCATACTTTC CAATTATGAGATGGACTGTGGGTACTGGGAGTGATCACTAACACCATAGTAATGTCTAATATTCACAGGCAGATCTGCTTGGGGAAGCTA GTTATGTGAAAGGCAAATAGAGTCATACAGTAGCTCAAAAGGCAACCATAATTCTCTTTGGTGCAGGTCTTGGGAGCGTGATCTAGATTA CACTGCACCATTCCCAAGTTAATCCCCTGAAAACTTACTCTCAACTGGAGCAAATGAACTTTGGTCCCAAATATCCATCTTTTCAGTAGC GTTAATTATGCTCTGTTTCCAACTGCATTTCCTTTCCAATTGAATTAAAGTGTGGCCTCGTTTTTAGTCATTTAAAATTGTTTTCTAAGT AATTGCTGCCTCTATTATGGCACTTCAATTTTGCACTGTCTTTTGAGATTCAAGAAAAATTTCTATTCTTTTTTTTGCATCCAATTGTGC CTGAACTTTTAAAATATGTAAATGCTGCCATGTTCCAAACCCATCGTCAGTGTGTGTGTTTAGAGCTGTGCACCCTAGAAACAACATATT GTCCCATGAGCAGGTGCCTGAGACACAGACCCCTTTGCATTCACAGAGAGGTCATTGGTTATAGAGACTTGAATTAATAAGTGACATTAT GCCAGTTTCTGTTCTCTCACAGGTGATAAACAATGCTTTTTGTGCACTACATACTCTTCAGTGTAGAGCTCTTGTTTTATGGGAAAAGGC TCAAATGCCAAATTGTGTTTGATGGATTAATATGCCCTTTTGCCGATGCATACTATTACTGATGTGACTCGGTTTTGTCGCAGCTTTGCT TTGTTTAATGAAACACACTTGTAAACCTCTTTTGCACTTTGAAAAAGAATCCAGCGGGATGCTCGAGCACCTGTAAACAATTTTCTCAAC >In-frame_ENST00000404338_ENST00000456483_TCGA-A8-A06O_ARHGAP35_chr19_47440665_+_ESR1_chr6_152201789_length(amino acids)=1544AA_start in transcript=0_stop in transcript=4634 MMMARKQDVRIPTYNISVVGLSGTEKEKGQCGIGKSCLCNRFVRPSADEFHLDHTSVLSTSDFGGRVVNNDHFLYWGEVSRSLEDCVECK MHIVEQTEFIDDQTFQPHRSTALQPYIKRAAATKLASAEKLMYFCTDQLGLEQDFEQKQMPDGKLLVDGFLLGIDVSRGMNRNFDDQLKF VSNLYNQLAKTKKPIVVVLTKCDEGVERYIRDAHTFALSKKNLQVVETSARSNVNVDLAFSTLVQLIDKSRGKTKIIPYFEALKQQSQQI ATAKDKYEWLVSRIVKNHNENWLSVSRKMQASPEYQDYVYLEGTQKAKKLFLQHIHRLKHEHIERRRKLYLAALPLAFEALIPNLDEIDH LSCIKAKKLLETKPEFLKWFVVLEETPWDATSHIDNMENERIPFDLMDTVPAEQLYEAHLEKLRNERKRVEMRRAFKENLETSPFITPGK PWEEARSFIMNEDFYQWLEESVYMDIYGKHQKQIIDKAKEEFQELLLEYSELFYELELDAKPSKEKMGVIQDVLGEEQRFKALQKLQAER DALILKHIHFVYHPTKETCPSCPACVDAKIEHLISSRFIRPSDRNQKNSLSDPNIDRINLVILGKDGLARELANEIRALCTNDDKYVIDG KMYELSLRPIEGNVRLPVNSFQTPTFQPHGCLCLYNSKESLSYVVESIEKSRESTLGRRDNHLVHLPLTLILVNKRGDTSGETLHSLIQQ GQQIASKLQCVFLDPASAGIGYGRNINEKQISQVLKGLLDSKRNLNLVSSTASIKDLADVDLRIVMCLMCGDPFSADDILFPVLQSQTCK SSHCGSNNSVLLELPIGLHKKRIELSVLSYHSSFSIRKSRLVHGYIVFYSAKRKASLAMLRAFLCEVQDIIPIQLVALTDGAVDVLDNDL SREQLTEGEEIAQEIDGRFTSIPCSQPQHKLEIFHPFFKDVVEKKNIIEATHMYDNAAEACSTTEEVFNSPRAGSPLCNSNLQDSEEDIE PSYSLFREDTSLPSLSKDHSKLSMELEGNDGLSFIMSNFESKLNNKVPPPVKPKPPVHFEITKGDLSYLDQGHRDGQRKSVSSSPWLPQD GFDPSDYAEPMDAVVKPRNEEENIYSVPHDSTQGKIITIRNINKAQSNGSGNGSDSEMDTSSLERGRKVSIVSKPVLYRTRCTRLGRFAS YRTSFSVGSDDELGPIRKKEEDQASQGYKGDNAVIPYETDEDPRRRNILRSLRRNTKKPKPKPRPSITKATWESNYFGVPLTTVVTPEKP IPIFIERCIEYIEATGHNDYMCPATNQCTIDKNRRKSCQACRLRKCYEVGMMKGGFVDLTLHDQVHLLECAWLEILMIGLVWRSMEHPGK LLFAPNLLLDRNQGKCVEGMVEIFDMLLATSSRFRMMNLQGEEFVCLKSIILLNSGVYTFLSSTLKSLEEKDHIHRVLDKITDTLIHLMA KAGLTLQQQHQRLAQLLLILSHIRHMSNKGMEHLYSMKCKNVVPLYDLLLEMLDAHRLHAPTSRGGASVEETDQSHLATAGSTSSHSLQK -------------------------------------------------------------- >In-frame_ENST00000404338_ENST00000443427_TCGA-A8-A06O_ARHGAP35_chr19_47440665_+_ESR1_chr6_152201789_length(transcript)=9279nt_BP=3826nt ATGATGATGGCAAGAAAGCAAGATGTCCGAATTCCCACCTACAACATCAGTGTGGTGGGATTATCTGGGACCGAGAAGGAAAAGGGCCAG TGTGGGATTGGAAAGTCTTGTTTGTGCAACCGCTTCGTGCGCCCGAGTGCTGACGAGTTTCACTTGGACCATACCTCCGTCCTCAGCACC AGTGACTTTGGAGGGCGAGTGGTCAATAATGACCACTTTCTCTACTGGGGAGAAGTTAGCCGCTCCCTGGAGGATTGTGTGGAATGTAAG ATGCACATTGTGGAGCAGACTGAATTTATTGATGATCAGACTTTTCAACCTCATCGAAGCACGGCCCTGCAGCCCTATATCAAGAGAGCT GCTGCGACCAAGCTTGCATCAGCTGAAAAACTCATGTACTTTTGCACTGACCAGCTGGGGCTGGAGCAGGACTTTGAGCAGAAACAAATG CCAGACGGAAAGCTGCTGGTTGATGGTTTTCTTCTTGGTATTGATGTTAGCAGGGGCATGAATAGGAACTTTGATGACCAGCTCAAGTTT GTCTCCAATCTCTACAATCAGCTTGCAAAAACAAAAAAGCCCATAGTGGTGGTCCTGACTAAGTGTGACGAAGGTGTTGAGCGGTACATT AGAGATGCACATACTTTTGCCTTAAGCAAAAAGAACCTCCAGGTTGTGGAGACCTCAGCGAGATCCAATGTAAACGTGGACTTGGCTTTC AGCACCTTAGTGCAACTCATTGATAAAAGTCGGGGAAAGACAAAAATCATTCCTTATTTTGAAGCTCTCAAGCAGCAGAGTCAGCAGATA GCTACAGCAAAAGACAAGTATGAGTGGCTGGTGAGTCGCATTGTGAAAAACCACAATGAGAACTGGCTGAGTGTCAGCCGAAAGATGCAG GCCTCTCCAGAATACCAGGACTATGTCTACCTGGAAGGGACTCAGAAAGCCAAGAAGCTGTTTCTACAGCACATCCACCGCCTCAAGCAT GAGCATATCGAGCGTAGGAGAAAGCTGTACCTGGCAGCCCTGCCATTAGCTTTTGAAGCTCTTATACCTAATCTAGATGAAATAGACCAC CTAAGCTGCATAAAAGCCAAAAAGCTCTTAGAAACCAAGCCAGAATTCTTGAAGTGGTTTGTTGTGCTTGAAGAGACCCCATGGGATGCC ACCAGTCACATTGACAACATGGAAAACGAACGGATTCCCTTTGATTTAATGGATACCGTCCCTGCAGAGCAGCTATACGAGGCCCACTTA GAGAAGCTGAGGAACGAAAGGAAAAGAGTTGAGATGCGAAGGGCGTTTAAAGAAAACCTGGAGACTTCTCCTTTCATAACTCCCGGAAAG CCTTGGGAAGAGGCCCGTAGTTTTATTATGAATGAGGATTTCTACCAGTGGCTGGAGGAATCTGTATACATGGATATTTATGGCAAACAC CAAAAGCAAATTATAGATAAAGCAAAGGAAGAATTTCAGGAGTTGCTTTTGGAATATTCAGAATTGTTTTATGAACTGGAGCTGGATGCT AAGCCCAGCAAGGAGAAGATGGGTGTTATTCAGGATGTTCTGGGAGAGGAACAGCGATTTAAAGCATTACAAAAGCTCCAAGCAGAGCGT GATGCCCTTATTCTGAAACACATTCATTTTGTGTACCACCCAACAAAGGAGACATGCCCCAGCTGCCCAGCTTGTGTGGACGCTAAGATT GAGCACTTGATTAGTTCTCGGTTTATCCGGCCGTCTGACCGGAATCAGAAAAATTCACTCTCTGACCCTAACATTGATAGAATCAACTTG GTTATATTGGGCAAAGACGGCCTTGCCCGAGAGTTGGCCAATGAGATTCGAGCTCTTTGTACAAATGATGACAAGTATGTGATAGATGGT AAAATGTATGAGCTTTCCCTGAGGCCAATAGAGGGGAATGTCAGGCTTCCTGTGAACTCTTTCCAGACGCCAACATTTCAGCCCCACGGC TGTCTCTGCCTTTACAATTCAAAGGAATCGCTATCCTATGTAGTGGAAAGTATAGAGAAGAGTAGAGAGTCCACGCTGGGCCGGCGGGAT AATCATTTAGTCCATCTCCCCCTTACATTAATTTTGGTTAACAAGAGAGGAGACACCAGTGGAGAGACTCTGCATAGCTTAATACAGCAA GGTCAACAAATTGCTAGCAAACTTCAGTGTGTCTTTCTCGACCCTGCTTCTGCTGGCATTGGTTACGGACGCAACATTAATGAAAAGCAA ATCAGTCAAGTTTTGAAGGGACTCCTGGACTCTAAGCGTAACTTAAACCTGGTCAGTTCTACTGCTAGCATCAAAGATTTGGCTGATGTT GATCTGCGAATTGTTATGTGTCTGATGTGTGGAGATCCTTTTAGTGCAGATGACATACTTTTTCCTGTCCTTCAGTCCCAAACCTGTAAA TCTTCCCATTGTGGAAGCAACAACTCTGTTTTACTTGAACTACCAATCGGACTGCACAAGAAGCGGATTGAACTGTCTGTTCTTTCATAC CATTCCTCCTTTAGCATCAGAAAGAGCCGGTTGGTTCATGGGTACATTGTTTTTTATTCAGCCAAACGTAAGGCCTCTTTGGCTATGTTA CGTGCCTTTCTTTGTGAAGTGCAGGATATTATCCCTATTCAGCTTGTAGCACTCACTGATGGCGCTGTAGATGTCCTGGACAATGACTTA AGTAGGGAACAGCTAACTGAGGGGGAGGAGATTGCTCAAGAAATTGACGGAAGGTTCACAAGCATCCCCTGTAGCCAACCCCAGCATAAA CTTGAGATCTTTCACCCATTTTTTAAAGATGTGGTGGAAAAAAAGAACATAATCGAGGCTACTCATATGTACGATAATGCTGCCGAGGCC TGTAGCACCACCGAAGAGGTGTTTAACTCCCCCCGGGCAGGATCACCGCTCTGCAACTCAAACCTGCAGGATTCAGAAGAAGATATCGAG CCATCTTACAGCCTGTTTCGAGAAGACACATCACTGCCTTCTCTGTCCAAAGACCATTCTAAGCTCTCTATGGAACTGGAGGGAAATGAT GGGCTGTCTTTCATTATGAGCAATTTTGAGAGTAAACTGAACAACAAAGTACCTCCGCCAGTCAAACCAAAGCCTCCTGTCCATTTTGAA ATTACAAAGGGGGATCTATCTTATTTAGACCAAGGCCATAGGGATGGACAGAGGAAGTCTGTGTCTTCTAGCCCCTGGCTGCCTCAGGAT GGGTTTGATCCTTCTGACTATGCTGAACCCATGGATGCTGTGGTGAAGCCAAGGAATGAAGAAGAAAACATATACTCCGTGCCCCATGAC AGCACCCAAGGCAAAATCATCACCATTCGGAATATCAACAAAGCCCAGTCCAACGGCAGCGGGAATGGTTCTGACAGTGAAATGGACACC AGCTCTCTAGAGCGAGGGCGCAAGGTTTCCATCGTGAGCAAGCCAGTGCTGTACAGGACGAGATGCACCCGGCTGGGGCGGTTTGCTAGT TACCGGACCAGCTTCAGCGTGGGGAGTGATGATGAGCTGGGGCCCATCCGGAAGAAAGAGGAGGATCAGGCATCCCAGGGTTATAAAGGG GACAATGCTGTCATTCCATACGAAACAGACGAAGACCCGCGGAGGAGGAATATTCTTCGCAGCCTAAGGAGGAACACTAAGAAACCAAAG CCCAAACCCCGGCCATCCATCACAAAGGCAACCTGGGAGAGTAACTATTTTGGGGTGCCCTTAACAACTGTCGTGACTCCAGAGAAGCCG ATCCCCATTTTTATTGAAAGATGTATTGAGTACATTGAAGCCACAGGACATAACGACTATATGTGTCCAGCCACCAACCAGTGCACCATT GATAAAAACAGGAGGAAGAGCTGCCAGGCCTGCCGGCTCCGTAAATGCTACGAAGTGGGAATGATGAAAGGTGGGATACGAAAAGACCGA AGAGGAGGGAGAATGTTGAAACACAAGCGCCAGAGAGATGATGGGGAGGGCAGGGGTGAAGTGGGGTCTGCTGGAGACATGAGAGCTGCC AACCTTTGGCCAAGCCCGCTCATGATCAAACGCTCTAAGAAGAACAGCCTGGCCTTGTCCCTGACGGCCGACCAGATGGTCAGTGCCTTG TTGGATGCTGAGCCCCCGATACTCTATTCCGAGTATGATCCTACCAGACCCTTCAGTGAAGCTTCGATGATGGGCTTACTGACCAACCTG GCAGACAGGGAGCTGGTTCACATGATCAACTGGGCGAAGAGGGTGCCAGGCTTTGTGGATTTGACCCTCCATGATCAGGTCCACCTTCTA GAATGTGCCTGGCTAGAGATCCTGATGATTGGTCTCGTCTGGCGCTCCATGGAGCACCCAGGGAAGCTACTGTTTGCTCCTAACTTGCTC TTGGACAGGAACCAGGGAAAATGTGTAGAGGGCATGGTGGAGATCTTCGACATGCTGCTGGCTACATCATCTCGGTTCCGCATGATGAAT CTGCAGGGAGAGGAGTTTGTGTGCCTCAAATCTATTATTTTGCTTAATTCTGGAGTGTACACATTTCTGTCCAGCACCCTGAAGTCTCTG GAAGAGAAGGACCATATCCACCGAGTCCTGGACAAGATCACAGACACTTTGATCCACCTGATGGCCAAGGCAGGCCTGACCCTGCAGCAG CAGCACCAGCGGCTGGCCCAGCTCCTCCTCATCCTCTCCCACATCAGGCACATGAGTAACAAAGGCATGGAGCATCTGTACAGCATGAAG TGCAAGAACGTGGTGCCCCTCTATGACCTGCTGCTGGAGATGCTGGACGCCCACCGCCTACATGCGCCCACTAGCCGTGGAGGGGCATCC GTGGAGGAGACGGACCAAAGCCACTTGGCCACTGCGGGCTCTACTTCATCGCATTCCTTGCAAAAGTATTACATCACGGGGGAGGCAGAG GGTTTCCCTGCCACGGTCTGAGAGCTCCCTGGCTCCCACACGGTTCAGATAATCCCTGCTGCATTTTACCCTCATCATGCACCACTTTAG CCAAATTCTGTCTCCTGCATACACTCCGGCATGCATCCAACACCAATGGCTTTCTAGATGAGTGGCCATTCATTTGCTTGCTCAGTTCTT AGTGGCACATCTTCTGTCTTCTGTTGGGAACAGCCAAAGGGATTCCAAGGCTAAATCTTTGTAACAGCTCTCTTTCCCCCTTGCTATGTT ACTAAGCGTGAGGATTCCCGTAGCTCTTCACAGCTGAACTCAGTCTATGGGTTGGGGCTCAGATAACTCTGTGCATTTAAGCTACTTGTA GAGACCCAGGCCTGGAGAGTAGACATTTTGCCTCTGATAAGCACTTTTTAAATGGCTCTAAGAATAAGCCACAGCAAAGAATTTAAAGTG GCTCCTTTAATTGGTGACTTGGAGAAAGCTAGGTCAAGGGTTTATTATAGCACCCTCTTGTATTCCTATGGCAATGCATCCTTTTATGAA AGTGGTACACCTTAAAGCTTTTATATGACTGTAGCAGAGTATCTGGTGATTGTCAATTCATTCCCCCTATAGGAATACAAGGGGCACACA GGGAAGGCAGATCCCCTAGTTGGCAAGACTATTTTAACTTGATACACTGCAGATTCAGATGTGCTGAAAGCTCTGCCTCTGGCTTTCCGG TCATGGGTTCCAGTTAATTCATGCCTCCCATGGACCTATGGAGAGCAGCAAGTTGATCTTAGTTAAGTCTCCCTATATGAGGGATAAGTT CCTGATTTTTGTTTTTATTTTTGTGTTACAAAAGAAAGCCCTCCCTCCCTGAACTTGCAGTAAGGTCAGCTTCAGGACCTGTTCCAGTGG GCACTGTACTTGGATCTTCCCGGCGTGTGTGTGCCTTACACAGGGGTGAACTGTTCACTGTGGTGATGCATGATGAGGGTAAATGGTAGT TGAAAGGAGCAGGGGCCCTGGTGTTGCATTTAGCCCTGGGGCATGGAGCTGAACAGTACTTGTGCAGGATTGTTGTGGCTACTAGAGAAC AAGAGGGAAAGTAGGGCAGAAACTGGATACAGTTCTGAGGCACAGCCAGACTTGCTCAGGGTGGCCCTGCCACAGGCTGCAGCTACCTAG GAACATTCCTTGCAGACCCCGCATTGCCCTTTGGGGGTGCCCTGGGATCCCTGGGGTAGTCCAGCTCTTCTTCATTTCCCAGCGTGGCCC TGGTTGGAAGAAGCAGCTGTCACAGCTGCTGTAGACAGCTGTGTTCCTACAATTGGCCCAGCACCCTGGGGCACGGGAGAAGGGTGGGGA CCGTTGCTGTCACTACTCAGGCTGACTGGGGCCTGGTCAGATTACGTATGCCCTTGGTGGTTTAGAGATAATCCAAAATCAGGGTTTGGT TTGGGGAAGAAAATCCTCCCCCTTCCTCCCCCGCCCCGTTCCCTACCGCCTCCACTCCTGCCAGCTCATTTCCTTCAATTTCCTTTGACC TATAGGCTAAAAAAGAAAGGCTCATTCCAGCCACAGGGCAGCCTTCCCTGGGCCTTTGCTTCTCTAGCACAATTATGGGTTACTTCCTTT TTCTTAACAAAAAAGAATGTTTGATTTCCTCTGGGTGACCTTATTGTCTGTAATTGAAACCCTATTGAGAGGTGATGTCTGTGTTAGCCA ATGACCCAGGTGAGCTGCTCGGGCTTCTCTTGGTATGTCTTGTTTGGAAAAGTGGATTTCATTCATTTCTGATTGTCCAGTTAAGTGATC ACCAAAGGACTGAGAATCTGGGAGGGCAAAAAAAAAAAAAAAGTTTTTATGTGCACTTAAATTTGGGGACAATTTTATGTATCTGTGTTA AGGATATGTTTAAGAACATAATTCTTTTGTTGCTGTTTGTTTAAGAAGCACCTTAGTTTGTTTAAGAAGCACCTTATATAGTATAATATA TATTTTTTTGAAATTACATTGCTTGTTTATCAGACAATTGAATGTAGTAATTCTGTTCTGGATTTAATTTGACTGGGTTAACATGCAAAA ACCAAGGAAAAATATTTAGTTTTTTTTTTTTTTTTTGTATACTTTTCAAGCTACCTTGTCATGTATACAGTCATTTATGCCTAAAGCCTG GTGATTATTCATTTAAATGAAGATCACATTTCATATCAACTTTTGTATCCACAGTAGACAAAATAGCACTAATCCAGATGCCTATTGTTG GATACTGAATGACAGACAATCTTATGTAGCAAAGATTATGCCTGAAAAGGAAAATTATTCAGGGCAGCTAATTTTGCTTTTACCAAAATA TCAGTAGTAATATTTTTGGACAGTAGCTAATGGGTCAGTGGGTTCTTTTTAATGTTTATACTTAGATTTTCTTTTAAAAAAATTAAAATA AAACAAAAAAAAATTTCTAGGACTAGACGATGTAATACCAGCTAAAGCCAAACAATTATACAGTGGAAGGTTTTACATTATTCATCCAAT GTGTTTCTATTCATGTTAAGATACTACTACATTTGAAGTGGGCAGAGAACATCAGATGATTGAAATGTTCGCCCAGGGGTCTCCAGCAAC TTTGGAAATCTCTTTGTATTTTTACTTGAAGTGCCACTAATGGACAGCAGATATTTTCTGGCTGATGTTGGTATTGGGTGTAGGAACATG ATTTAAAAAAAAACTCTTGCCTCTGCTTTCCCCCACTCTGAGGCAAGTTAAAATGTAAAAGATGTGATTTATCTGGGGGGCTCAGGTATG GTGGGGAAGTGGATTCAGGAATCTGGGGAATGGCAAATATATTAAGAAGAGTATTGAAAGTATTTGGAGGAAAATGGTTAATTCTGGGTG TGCACCAGGGTTCAGTAGAGTCCACTTCTGCCCTGGAGACCACAAATCAACTAGCTCCATTTACAGCCATTTCTAAAATGGCAGCTTCAG TTCTAGAGAAGAAAGAACAACATCAGCAGTAAAGTCCATGGAATAGCTAGTGGTCTGTGTTTCTTTTCGCCATTGCCTAGCTTGCCGTAA TGATTCTATAATGCCATCATGCAGCAATTATGAGAGGCTAGGTCATCCAAAGAGAAGACCCTATCAATGTAGGTTGCAAAATCTAACCCC TAAGGAAGTGCAGTCTTTGATTTGATTTCCCTAGTAACCTTGCAGATATGTTTAACCAAGCCATAGCCCATGCCTTTTGAGGGCTGAACA AATAAGGGACTTACTGATAATTTACTTTTGATCACATTAAGGTGTTCTCACCTTGAAATCTTATACACTGAAATGGCCATTGATTTAGGC CACTGGCTTAGAGTACTCCTTCCCCTGCATGACACTGATTACAAATACTTTCCTATTCATACTTTCCAATTATGAGATGGACTGTGGGTA CTGGGAGTGATCACTAACACCATAGTAATGTCTAATATTCACAGGCAGATCTGCTTGGGGAAGCTAGTTATGTGAAAGGCAAATAGAGTC ATACAGTAGCTCAAAAGGCAACCATAATTCTCTTTGGTGCAGGTCTTGGGAGCGTGATCTAGATTACACTGCACCATTCCCAAGTTAATC CCCTGAAAACTTACTCTCAACTGGAGCAAATGAACTTTGGTCCCAAATATCCATCTTTTCAGTAGCGTTAATTATGCTCTGTTTCCAACT GCATTTCCTTTCCAATTGAATTAAAGTGTGGCCTCGTTTTTAGTCATTTAAAATTGTTTTCTAAGTAATTGCTGCCTCTATTATGGCACT TCAATTTTGCACTGTCTTTTGAGATTCAAGAAAAATTTCTATTCTTTTTTTTGCATCCAATTGTGCCTGAACTTTTAAAATATGTAAATG CTGCCATGTTCCAAACCCATCGTCAGTGTGTGTGTTTAGAGCTGTGCACCCTAGAAACAACATATTGTCCCATGAGCAGGTGCCTGAGAC ACAGACCCCTTTGCATTCACAGAGAGGTCATTGGTTATAGAGACTTGAATTAATAAGTGACATTATGCCAGTTTCTGTTCTCTCACAGGT GATAAACAATGCTTTTTGTGCACTACATACTCTTCAGTGTAGAGCTCTTGTTTTATGGGAAAAGGCTCAAATGCCAAATTGTGTTTGATG GATTAATATGCCCTTTTGCCGATGCATACTATTACTGATGTGACTCGGTTTTGTCGCAGCTTTGCTTTGTTTAATGAAACACACTTGTAA ACCTCTTTTGCACTTTGAAAAAGAATCCAGCGGGATGCTCGAGCACCTGTAAACAATTTTCTCAACCTATTTGATGTTCAAATAAAGAAT >In-frame_ENST00000404338_ENST00000443427_TCGA-A8-A06O_ARHGAP35_chr19_47440665_+_ESR1_chr6_152201789_length(amino acids)=1656AA_start in transcript=0_stop in transcript=4970 MMMARKQDVRIPTYNISVVGLSGTEKEKGQCGIGKSCLCNRFVRPSADEFHLDHTSVLSTSDFGGRVVNNDHFLYWGEVSRSLEDCVECK MHIVEQTEFIDDQTFQPHRSTALQPYIKRAAATKLASAEKLMYFCTDQLGLEQDFEQKQMPDGKLLVDGFLLGIDVSRGMNRNFDDQLKF VSNLYNQLAKTKKPIVVVLTKCDEGVERYIRDAHTFALSKKNLQVVETSARSNVNVDLAFSTLVQLIDKSRGKTKIIPYFEALKQQSQQI ATAKDKYEWLVSRIVKNHNENWLSVSRKMQASPEYQDYVYLEGTQKAKKLFLQHIHRLKHEHIERRRKLYLAALPLAFEALIPNLDEIDH LSCIKAKKLLETKPEFLKWFVVLEETPWDATSHIDNMENERIPFDLMDTVPAEQLYEAHLEKLRNERKRVEMRRAFKENLETSPFITPGK PWEEARSFIMNEDFYQWLEESVYMDIYGKHQKQIIDKAKEEFQELLLEYSELFYELELDAKPSKEKMGVIQDVLGEEQRFKALQKLQAER DALILKHIHFVYHPTKETCPSCPACVDAKIEHLISSRFIRPSDRNQKNSLSDPNIDRINLVILGKDGLARELANEIRALCTNDDKYVIDG KMYELSLRPIEGNVRLPVNSFQTPTFQPHGCLCLYNSKESLSYVVESIEKSRESTLGRRDNHLVHLPLTLILVNKRGDTSGETLHSLIQQ GQQIASKLQCVFLDPASAGIGYGRNINEKQISQVLKGLLDSKRNLNLVSSTASIKDLADVDLRIVMCLMCGDPFSADDILFPVLQSQTCK SSHCGSNNSVLLELPIGLHKKRIELSVLSYHSSFSIRKSRLVHGYIVFYSAKRKASLAMLRAFLCEVQDIIPIQLVALTDGAVDVLDNDL SREQLTEGEEIAQEIDGRFTSIPCSQPQHKLEIFHPFFKDVVEKKNIIEATHMYDNAAEACSTTEEVFNSPRAGSPLCNSNLQDSEEDIE PSYSLFREDTSLPSLSKDHSKLSMELEGNDGLSFIMSNFESKLNNKVPPPVKPKPPVHFEITKGDLSYLDQGHRDGQRKSVSSSPWLPQD GFDPSDYAEPMDAVVKPRNEEENIYSVPHDSTQGKIITIRNINKAQSNGSGNGSDSEMDTSSLERGRKVSIVSKPVLYRTRCTRLGRFAS YRTSFSVGSDDELGPIRKKEEDQASQGYKGDNAVIPYETDEDPRRRNILRSLRRNTKKPKPKPRPSITKATWESNYFGVPLTTVVTPEKP IPIFIERCIEYIEATGHNDYMCPATNQCTIDKNRRKSCQACRLRKCYEVGMMKGGIRKDRRGGRMLKHKRQRDDGEGRGEVGSAGDMRAA NLWPSPLMIKRSKKNSLALSLTADQMVSALLDAEPPILYSEYDPTRPFSEASMMGLLTNLADRELVHMINWAKRVPGFVDLTLHDQVHLL ECAWLEILMIGLVWRSMEHPGKLLFAPNLLLDRNQGKCVEGMVEIFDMLLATSSRFRMMNLQGEEFVCLKSIILLNSGVYTFLSSTLKSL EEKDHIHRVLDKITDTLIHLMAKAGLTLQQQHQRLAQLLLILSHIRHMSNKGMEHLYSMKCKNVVPLYDLLLEMLDAHRLHAPTSRGGAS -------------------------------------------------------------- >In-frame_ENST00000404338_ENST00000206249_TCGA-A8-A06O_ARHGAP35_chr19_47440665_+_ESR1_chr6_152201789_length(transcript)=9276nt_BP=3826nt ATGATGATGGCAAGAAAGCAAGATGTCCGAATTCCCACCTACAACATCAGTGTGGTGGGATTATCTGGGACCGAGAAGGAAAAGGGCCAG TGTGGGATTGGAAAGTCTTGTTTGTGCAACCGCTTCGTGCGCCCGAGTGCTGACGAGTTTCACTTGGACCATACCTCCGTCCTCAGCACC AGTGACTTTGGAGGGCGAGTGGTCAATAATGACCACTTTCTCTACTGGGGAGAAGTTAGCCGCTCCCTGGAGGATTGTGTGGAATGTAAG ATGCACATTGTGGAGCAGACTGAATTTATTGATGATCAGACTTTTCAACCTCATCGAAGCACGGCCCTGCAGCCCTATATCAAGAGAGCT GCTGCGACCAAGCTTGCATCAGCTGAAAAACTCATGTACTTTTGCACTGACCAGCTGGGGCTGGAGCAGGACTTTGAGCAGAAACAAATG CCAGACGGAAAGCTGCTGGTTGATGGTTTTCTTCTTGGTATTGATGTTAGCAGGGGCATGAATAGGAACTTTGATGACCAGCTCAAGTTT GTCTCCAATCTCTACAATCAGCTTGCAAAAACAAAAAAGCCCATAGTGGTGGTCCTGACTAAGTGTGACGAAGGTGTTGAGCGGTACATT AGAGATGCACATACTTTTGCCTTAAGCAAAAAGAACCTCCAGGTTGTGGAGACCTCAGCGAGATCCAATGTAAACGTGGACTTGGCTTTC AGCACCTTAGTGCAACTCATTGATAAAAGTCGGGGAAAGACAAAAATCATTCCTTATTTTGAAGCTCTCAAGCAGCAGAGTCAGCAGATA GCTACAGCAAAAGACAAGTATGAGTGGCTGGTGAGTCGCATTGTGAAAAACCACAATGAGAACTGGCTGAGTGTCAGCCGAAAGATGCAG GCCTCTCCAGAATACCAGGACTATGTCTACCTGGAAGGGACTCAGAAAGCCAAGAAGCTGTTTCTACAGCACATCCACCGCCTCAAGCAT GAGCATATCGAGCGTAGGAGAAAGCTGTACCTGGCAGCCCTGCCATTAGCTTTTGAAGCTCTTATACCTAATCTAGATGAAATAGACCAC CTAAGCTGCATAAAAGCCAAAAAGCTCTTAGAAACCAAGCCAGAATTCTTGAAGTGGTTTGTTGTGCTTGAAGAGACCCCATGGGATGCC ACCAGTCACATTGACAACATGGAAAACGAACGGATTCCCTTTGATTTAATGGATACCGTCCCTGCAGAGCAGCTATACGAGGCCCACTTA GAGAAGCTGAGGAACGAAAGGAAAAGAGTTGAGATGCGAAGGGCGTTTAAAGAAAACCTGGAGACTTCTCCTTTCATAACTCCCGGAAAG CCTTGGGAAGAGGCCCGTAGTTTTATTATGAATGAGGATTTCTACCAGTGGCTGGAGGAATCTGTATACATGGATATTTATGGCAAACAC CAAAAGCAAATTATAGATAAAGCAAAGGAAGAATTTCAGGAGTTGCTTTTGGAATATTCAGAATTGTTTTATGAACTGGAGCTGGATGCT AAGCCCAGCAAGGAGAAGATGGGTGTTATTCAGGATGTTCTGGGAGAGGAACAGCGATTTAAAGCATTACAAAAGCTCCAAGCAGAGCGT GATGCCCTTATTCTGAAACACATTCATTTTGTGTACCACCCAACAAAGGAGACATGCCCCAGCTGCCCAGCTTGTGTGGACGCTAAGATT GAGCACTTGATTAGTTCTCGGTTTATCCGGCCGTCTGACCGGAATCAGAAAAATTCACTCTCTGACCCTAACATTGATAGAATCAACTTG GTTATATTGGGCAAAGACGGCCTTGCCCGAGAGTTGGCCAATGAGATTCGAGCTCTTTGTACAAATGATGACAAGTATGTGATAGATGGT AAAATGTATGAGCTTTCCCTGAGGCCAATAGAGGGGAATGTCAGGCTTCCTGTGAACTCTTTCCAGACGCCAACATTTCAGCCCCACGGC TGTCTCTGCCTTTACAATTCAAAGGAATCGCTATCCTATGTAGTGGAAAGTATAGAGAAGAGTAGAGAGTCCACGCTGGGCCGGCGGGAT AATCATTTAGTCCATCTCCCCCTTACATTAATTTTGGTTAACAAGAGAGGAGACACCAGTGGAGAGACTCTGCATAGCTTAATACAGCAA GGTCAACAAATTGCTAGCAAACTTCAGTGTGTCTTTCTCGACCCTGCTTCTGCTGGCATTGGTTACGGACGCAACATTAATGAAAAGCAA ATCAGTCAAGTTTTGAAGGGACTCCTGGACTCTAAGCGTAACTTAAACCTGGTCAGTTCTACTGCTAGCATCAAAGATTTGGCTGATGTT GATCTGCGAATTGTTATGTGTCTGATGTGTGGAGATCCTTTTAGTGCAGATGACATACTTTTTCCTGTCCTTCAGTCCCAAACCTGTAAA TCTTCCCATTGTGGAAGCAACAACTCTGTTTTACTTGAACTACCAATCGGACTGCACAAGAAGCGGATTGAACTGTCTGTTCTTTCATAC CATTCCTCCTTTAGCATCAGAAAGAGCCGGTTGGTTCATGGGTACATTGTTTTTTATTCAGCCAAACGTAAGGCCTCTTTGGCTATGTTA CGTGCCTTTCTTTGTGAAGTGCAGGATATTATCCCTATTCAGCTTGTAGCACTCACTGATGGCGCTGTAGATGTCCTGGACAATGACTTA AGTAGGGAACAGCTAACTGAGGGGGAGGAGATTGCTCAAGAAATTGACGGAAGGTTCACAAGCATCCCCTGTAGCCAACCCCAGCATAAA CTTGAGATCTTTCACCCATTTTTTAAAGATGTGGTGGAAAAAAAGAACATAATCGAGGCTACTCATATGTACGATAATGCTGCCGAGGCC TGTAGCACCACCGAAGAGGTGTTTAACTCCCCCCGGGCAGGATCACCGCTCTGCAACTCAAACCTGCAGGATTCAGAAGAAGATATCGAG CCATCTTACAGCCTGTTTCGAGAAGACACATCACTGCCTTCTCTGTCCAAAGACCATTCTAAGCTCTCTATGGAACTGGAGGGAAATGAT GGGCTGTCTTTCATTATGAGCAATTTTGAGAGTAAACTGAACAACAAAGTACCTCCGCCAGTCAAACCAAAGCCTCCTGTCCATTTTGAA ATTACAAAGGGGGATCTATCTTATTTAGACCAAGGCCATAGGGATGGACAGAGGAAGTCTGTGTCTTCTAGCCCCTGGCTGCCTCAGGAT GGGTTTGATCCTTCTGACTATGCTGAACCCATGGATGCTGTGGTGAAGCCAAGGAATGAAGAAGAAAACATATACTCCGTGCCCCATGAC AGCACCCAAGGCAAAATCATCACCATTCGGAATATCAACAAAGCCCAGTCCAACGGCAGCGGGAATGGTTCTGACAGTGAAATGGACACC AGCTCTCTAGAGCGAGGGCGCAAGGTTTCCATCGTGAGCAAGCCAGTGCTGTACAGGACGAGATGCACCCGGCTGGGGCGGTTTGCTAGT TACCGGACCAGCTTCAGCGTGGGGAGTGATGATGAGCTGGGGCCCATCCGGAAGAAAGAGGAGGATCAGGCATCCCAGGGTTATAAAGGG GACAATGCTGTCATTCCATACGAAACAGACGAAGACCCGCGGAGGAGGAATATTCTTCGCAGCCTAAGGAGGAACACTAAGAAACCAAAG CCCAAACCCCGGCCATCCATCACAAAGGCAACCTGGGAGAGTAACTATTTTGGGGTGCCCTTAACAACTGTCGTGACTCCAGAGAAGCCG ATCCCCATTTTTATTGAAAGATGTATTGAGTACATTGAAGCCACAGGACATAACGACTATATGTGTCCAGCCACCAACCAGTGCACCATT GATAAAAACAGGAGGAAGAGCTGCCAGGCCTGCCGGCTCCGTAAATGCTACGAAGTGGGAATGATGAAAGGTGGGATACGAAAAGACCGA AGAGGAGGGAGAATGTTGAAACACAAGCGCCAGAGAGATGATGGGGAGGGCAGGGGTGAAGTGGGGTCTGCTGGAGACATGAGAGCTGCC AACCTTTGGCCAAGCCCGCTCATGATCAAACGCTCTAAGAAGAACAGCCTGGCCTTGTCCCTGACGGCCGACCAGATGGTCAGTGCCTTG TTGGATGCTGAGCCCCCGATACTCTATTCCGAGTATGATCCTACCAGACCCTTCAGTGAAGCTTCGATGATGGGCTTACTGACCAACCTG GCAGACAGGGAGCTGGTTCACATGATCAACTGGGCGAAGAGGGTGCCAGGCTTTGTGGATTTGACCCTCCATGATCAGGTCCACCTTCTA GAATGTGCCTGGCTAGAGATCCTGATGATTGGTCTCGTCTGGCGCTCCATGGAGCACCCAGGGAAGCTACTGTTTGCTCCTAACTTGCTC TTGGACAGGAACCAGGGAAAATGTGTAGAGGGCATGGTGGAGATCTTCGACATGCTGCTGGCTACATCATCTCGGTTCCGCATGATGAAT CTGCAGGGAGAGGAGTTTGTGTGCCTCAAATCTATTATTTTGCTTAATTCTGGAGTGTACACATTTCTGTCCAGCACCCTGAAGTCTCTG GAAGAGAAGGACCATATCCACCGAGTCCTGGACAAGATCACAGACACTTTGATCCACCTGATGGCCAAGGCAGGCCTGACCCTGCAGCAG CAGCACCAGCGGCTGGCCCAGCTCCTCCTCATCCTCTCCCACATCAGGCACATGAGTAACAAAGGCATGGAGCATCTGTACAGCATGAAG TGCAAGAACGTGGTGCCCCTCTATGACCTGCTGCTGGAGATGCTGGACGCCCACCGCCTACATGCGCCCACTAGCCGTGGAGGGGCATCC GTGGAGGAGACGGACCAAAGCCACTTGGCCACTGCGGGCTCTACTTCATCGCATTCCTTGCAAAAGTATTACATCACGGGGGAGGCAGAG GGTTTCCCTGCCACGGTCTGAGAGCTCCCTGGCTCCCACACGGTTCAGATAATCCCTGCTGCATTTTACCCTCATCATGCACCACTTTAG CCAAATTCTGTCTCCTGCATACACTCCGGCATGCATCCAACACCAATGGCTTTCTAGATGAGTGGCCATTCATTTGCTTGCTCAGTTCTT AGTGGCACATCTTCTGTCTTCTGTTGGGAACAGCCAAAGGGATTCCAAGGCTAAATCTTTGTAACAGCTCTCTTTCCCCCTTGCTATGTT ACTAAGCGTGAGGATTCCCGTAGCTCTTCACAGCTGAACTCAGTCTATGGGTTGGGGCTCAGATAACTCTGTGCATTTAAGCTACTTGTA GAGACCCAGGCCTGGAGAGTAGACATTTTGCCTCTGATAAGCACTTTTTAAATGGCTCTAAGAATAAGCCACAGCAAAGAATTTAAAGTG GCTCCTTTAATTGGTGACTTGGAGAAAGCTAGGTCAAGGGTTTATTATAGCACCCTCTTGTATTCCTATGGCAATGCATCCTTTTATGAA AGTGGTACACCTTAAAGCTTTTATATGACTGTAGCAGAGTATCTGGTGATTGTCAATTCATTCCCCCTATAGGAATACAAGGGGCACACA GGGAAGGCAGATCCCCTAGTTGGCAAGACTATTTTAACTTGATACACTGCAGATTCAGATGTGCTGAAAGCTCTGCCTCTGGCTTTCCGG TCATGGGTTCCAGTTAATTCATGCCTCCCATGGACCTATGGAGAGCAGCAAGTTGATCTTAGTTAAGTCTCCCTATATGAGGGATAAGTT CCTGATTTTTGTTTTTATTTTTGTGTTACAAAAGAAAGCCCTCCCTCCCTGAACTTGCAGTAAGGTCAGCTTCAGGACCTGTTCCAGTGG GCACTGTACTTGGATCTTCCCGGCGTGTGTGTGCCTTACACAGGGGTGAACTGTTCACTGTGGTGATGCATGATGAGGGTAAATGGTAGT TGAAAGGAGCAGGGGCCCTGGTGTTGCATTTAGCCCTGGGGCATGGAGCTGAACAGTACTTGTGCAGGATTGTTGTGGCTACTAGAGAAC AAGAGGGAAAGTAGGGCAGAAACTGGATACAGTTCTGAGGCACAGCCAGACTTGCTCAGGGTGGCCCTGCCACAGGCTGCAGCTACCTAG GAACATTCCTTGCAGACCCCGCATTGCCCTTTGGGGGTGCCCTGGGATCCCTGGGGTAGTCCAGCTCTTCTTCATTTCCCAGCGTGGCCC TGGTTGGAAGAAGCAGCTGTCACAGCTGCTGTAGACAGCTGTGTTCCTACAATTGGCCCAGCACCCTGGGGCACGGGAGAAGGGTGGGGA CCGTTGCTGTCACTACTCAGGCTGACTGGGGCCTGGTCAGATTACGTATGCCCTTGGTGGTTTAGAGATAATCCAAAATCAGGGTTTGGT TTGGGGAAGAAAATCCTCCCCCTTCCTCCCCCGCCCCGTTCCCTACCGCCTCCACTCCTGCCAGCTCATTTCCTTCAATTTCCTTTGACC TATAGGCTAAAAAAGAAAGGCTCATTCCAGCCACAGGGCAGCCTTCCCTGGGCCTTTGCTTCTCTAGCACAATTATGGGTTACTTCCTTT TTCTTAACAAAAAAGAATGTTTGATTTCCTCTGGGTGACCTTATTGTCTGTAATTGAAACCCTATTGAGAGGTGATGTCTGTGTTAGCCA ATGACCCAGGTGAGCTGCTCGGGCTTCTCTTGGTATGTCTTGTTTGGAAAAGTGGATTTCATTCATTTCTGATTGTCCAGTTAAGTGATC ACCAAAGGACTGAGAATCTGGGAGGGCAAAAAAAAAAAAAAAGTTTTTATGTGCACTTAAATTTGGGGACAATTTTATGTATCTGTGTTA AGGATATGTTTAAGAACATAATTCTTTTGTTGCTGTTTGTTTAAGAAGCACCTTAGTTTGTTTAAGAAGCACCTTATATAGTATAATATA TATTTTTTTGAAATTACATTGCTTGTTTATCAGACAATTGAATGTAGTAATTCTGTTCTGGATTTAATTTGACTGGGTTAACATGCAAAA ACCAAGGAAAAATATTTAGTTTTTTTTTTTTTTTTTGTATACTTTTCAAGCTACCTTGTCATGTATACAGTCATTTATGCCTAAAGCCTG GTGATTATTCATTTAAATGAAGATCACATTTCATATCAACTTTTGTATCCACAGTAGACAAAATAGCACTAATCCAGATGCCTATTGTTG GATACTGAATGACAGACAATCTTATGTAGCAAAGATTATGCCTGAAAAGGAAAATTATTCAGGGCAGCTAATTTTGCTTTTACCAAAATA TCAGTAGTAATATTTTTGGACAGTAGCTAATGGGTCAGTGGGTTCTTTTTAATGTTTATACTTAGATTTTCTTTTAAAAAAATTAAAATA AAACAAAAAAAAATTTCTAGGACTAGACGATGTAATACCAGCTAAAGCCAAACAATTATACAGTGGAAGGTTTTACATTATTCATCCAAT GTGTTTCTATTCATGTTAAGATACTACTACATTTGAAGTGGGCAGAGAACATCAGATGATTGAAATGTTCGCCCAGGGGTCTCCAGCAAC TTTGGAAATCTCTTTGTATTTTTACTTGAAGTGCCACTAATGGACAGCAGATATTTTCTGGCTGATGTTGGTATTGGGTGTAGGAACATG ATTTAAAAAAAAACTCTTGCCTCTGCTTTCCCCCACTCTGAGGCAAGTTAAAATGTAAAAGATGTGATTTATCTGGGGGGCTCAGGTATG GTGGGGAAGTGGATTCAGGAATCTGGGGAATGGCAAATATATTAAGAAGAGTATTGAAAGTATTTGGAGGAAAATGGTTAATTCTGGGTG TGCACCAGGGTTCAGTAGAGTCCACTTCTGCCCTGGAGACCACAAATCAACTAGCTCCATTTACAGCCATTTCTAAAATGGCAGCTTCAG TTCTAGAGAAGAAAGAACAACATCAGCAGTAAAGTCCATGGAATAGCTAGTGGTCTGTGTTTCTTTTCGCCATTGCCTAGCTTGCCGTAA TGATTCTATAATGCCATCATGCAGCAATTATGAGAGGCTAGGTCATCCAAAGAGAAGACCCTATCAATGTAGGTTGCAAAATCTAACCCC TAAGGAAGTGCAGTCTTTGATTTGATTTCCCTAGTAACCTTGCAGATATGTTTAACCAAGCCATAGCCCATGCCTTTTGAGGGCTGAACA AATAAGGGACTTACTGATAATTTACTTTTGATCACATTAAGGTGTTCTCACCTTGAAATCTTATACACTGAAATGGCCATTGATTTAGGC CACTGGCTTAGAGTACTCCTTCCCCTGCATGACACTGATTACAAATACTTTCCTATTCATACTTTCCAATTATGAGATGGACTGTGGGTA CTGGGAGTGATCACTAACACCATAGTAATGTCTAATATTCACAGGCAGATCTGCTTGGGGAAGCTAGTTATGTGAAAGGCAAATAGAGTC ATACAGTAGCTCAAAAGGCAACCATAATTCTCTTTGGTGCAGGTCTTGGGAGCGTGATCTAGATTACACTGCACCATTCCCAAGTTAATC CCCTGAAAACTTACTCTCAACTGGAGCAAATGAACTTTGGTCCCAAATATCCATCTTTTCAGTAGCGTTAATTATGCTCTGTTTCCAACT GCATTTCCTTTCCAATTGAATTAAAGTGTGGCCTCGTTTTTAGTCATTTAAAATTGTTTTCTAAGTAATTGCTGCCTCTATTATGGCACT TCAATTTTGCACTGTCTTTTGAGATTCAAGAAAAATTTCTATTCTTTTTTTTGCATCCAATTGTGCCTGAACTTTTAAAATATGTAAATG CTGCCATGTTCCAAACCCATCGTCAGTGTGTGTGTTTAGAGCTGTGCACCCTAGAAACAACATATTGTCCCATGAGCAGGTGCCTGAGAC ACAGACCCCTTTGCATTCACAGAGAGGTCATTGGTTATAGAGACTTGAATTAATAAGTGACATTATGCCAGTTTCTGTTCTCTCACAGGT GATAAACAATGCTTTTTGTGCACTACATACTCTTCAGTGTAGAGCTCTTGTTTTATGGGAAAAGGCTCAAATGCCAAATTGTGTTTGATG GATTAATATGCCCTTTTGCCGATGCATACTATTACTGATGTGACTCGGTTTTGTCGCAGCTTTGCTTTGTTTAATGAAACACACTTGTAA ACCTCTTTTGCACTTTGAAAAAGAATCCAGCGGGATGCTCGAGCACCTGTAAACAATTTTCTCAACCTATTTGATGTTCAAATAAAGAAT >In-frame_ENST00000404338_ENST00000206249_TCGA-A8-A06O_ARHGAP35_chr19_47440665_+_ESR1_chr6_152201789_length(amino acids)=1656AA_start in transcript=0_stop in transcript=4970 MMMARKQDVRIPTYNISVVGLSGTEKEKGQCGIGKSCLCNRFVRPSADEFHLDHTSVLSTSDFGGRVVNNDHFLYWGEVSRSLEDCVECK MHIVEQTEFIDDQTFQPHRSTALQPYIKRAAATKLASAEKLMYFCTDQLGLEQDFEQKQMPDGKLLVDGFLLGIDVSRGMNRNFDDQLKF VSNLYNQLAKTKKPIVVVLTKCDEGVERYIRDAHTFALSKKNLQVVETSARSNVNVDLAFSTLVQLIDKSRGKTKIIPYFEALKQQSQQI ATAKDKYEWLVSRIVKNHNENWLSVSRKMQASPEYQDYVYLEGTQKAKKLFLQHIHRLKHEHIERRRKLYLAALPLAFEALIPNLDEIDH LSCIKAKKLLETKPEFLKWFVVLEETPWDATSHIDNMENERIPFDLMDTVPAEQLYEAHLEKLRNERKRVEMRRAFKENLETSPFITPGK PWEEARSFIMNEDFYQWLEESVYMDIYGKHQKQIIDKAKEEFQELLLEYSELFYELELDAKPSKEKMGVIQDVLGEEQRFKALQKLQAER DALILKHIHFVYHPTKETCPSCPACVDAKIEHLISSRFIRPSDRNQKNSLSDPNIDRINLVILGKDGLARELANEIRALCTNDDKYVIDG KMYELSLRPIEGNVRLPVNSFQTPTFQPHGCLCLYNSKESLSYVVESIEKSRESTLGRRDNHLVHLPLTLILVNKRGDTSGETLHSLIQQ GQQIASKLQCVFLDPASAGIGYGRNINEKQISQVLKGLLDSKRNLNLVSSTASIKDLADVDLRIVMCLMCGDPFSADDILFPVLQSQTCK SSHCGSNNSVLLELPIGLHKKRIELSVLSYHSSFSIRKSRLVHGYIVFYSAKRKASLAMLRAFLCEVQDIIPIQLVALTDGAVDVLDNDL SREQLTEGEEIAQEIDGRFTSIPCSQPQHKLEIFHPFFKDVVEKKNIIEATHMYDNAAEACSTTEEVFNSPRAGSPLCNSNLQDSEEDIE PSYSLFREDTSLPSLSKDHSKLSMELEGNDGLSFIMSNFESKLNNKVPPPVKPKPPVHFEITKGDLSYLDQGHRDGQRKSVSSSPWLPQD GFDPSDYAEPMDAVVKPRNEEENIYSVPHDSTQGKIITIRNINKAQSNGSGNGSDSEMDTSSLERGRKVSIVSKPVLYRTRCTRLGRFAS YRTSFSVGSDDELGPIRKKEEDQASQGYKGDNAVIPYETDEDPRRRNILRSLRRNTKKPKPKPRPSITKATWESNYFGVPLTTVVTPEKP IPIFIERCIEYIEATGHNDYMCPATNQCTIDKNRRKSCQACRLRKCYEVGMMKGGIRKDRRGGRMLKHKRQRDDGEGRGEVGSAGDMRAA NLWPSPLMIKRSKKNSLALSLTADQMVSALLDAEPPILYSEYDPTRPFSEASMMGLLTNLADRELVHMINWAKRVPGFVDLTLHDQVHLL ECAWLEILMIGLVWRSMEHPGKLLFAPNLLLDRNQGKCVEGMVEIFDMLLATSSRFRMMNLQGEEFVCLKSIILLNSGVYTFLSSTLKSL EEKDHIHRVLDKITDTLIHLMAKAGLTLQQQHQRLAQLLLILSHIRHMSNKGMEHLYSMKCKNVVPLYDLLLEMLDAHRLHAPTSRGGAS -------------------------------------------------------------- |
Top |
Fusion Gene PPI Analysis for ARHGAP35-ESR1 |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| Tgene | ESR1 | chr19:47440665 | chr6:152201789 | ENST00000206249 | 1 | 8 | 262_595 | 214.33333333333334 | 596.0 | AKAP13 | |
| Tgene | ESR1 | chr19:47440665 | chr6:152201789 | ENST00000338799 | 2 | 9 | 262_595 | 214.33333333333334 | 596.0 | AKAP13 | |
| Tgene | ESR1 | chr19:47440665 | chr6:152201789 | ENST00000440973 | 3 | 10 | 262_595 | 214.33333333333334 | 596.0 | AKAP13 | |
| Tgene | ESR1 | chr19:47440665 | chr6:152201789 | ENST00000443427 | 2 | 9 | 262_595 | 214.33333333333334 | 596.0 | AKAP13 | |
| Tgene | ESR1 | chr19:47440665 | chr6:152201789 | ENST00000456483 | 2 | 8 | 262_595 | 214.33333333333334 | 484.0 | AKAP13 |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| Tgene | ESR1 | chr19:47440665 | chr6:152201789 | ENST00000206249 | 1 | 8 | 35_174 | 214.33333333333334 | 596.0 | DDX5%3B self-association | |
| Tgene | ESR1 | chr19:47440665 | chr6:152201789 | ENST00000338799 | 2 | 9 | 35_174 | 214.33333333333334 | 596.0 | DDX5%3B self-association | |
| Tgene | ESR1 | chr19:47440665 | chr6:152201789 | ENST00000440973 | 3 | 10 | 35_174 | 214.33333333333334 | 596.0 | DDX5%3B self-association | |
| Tgene | ESR1 | chr19:47440665 | chr6:152201789 | ENST00000443427 | 2 | 9 | 35_174 | 214.33333333333334 | 596.0 | DDX5%3B self-association | |
| Tgene | ESR1 | chr19:47440665 | chr6:152201789 | ENST00000456483 | 2 | 8 | 35_174 | 214.33333333333334 | 484.0 | DDX5%3B self-association |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs for ARHGAP35-ESR1 |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.8 2021-05-08) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
| Tgene | ESR1 | P03372 | DB00286 | Conjugated estrogens | Agonist | Small molecule | Approved |
| Tgene | ESR1 | P03372 | DB00286 | Conjugated estrogens | Agonist | Small molecule | Approved |
| Tgene | ESR1 | P03372 | DB00286 | Conjugated estrogens | Agonist | Small molecule | Approved |
| Tgene | ESR1 | P03372 | DB00304 | Desogestrel | Agonist | Small molecule | Approved |
| Tgene | ESR1 | P03372 | DB00304 | Desogestrel | Agonist | Small molecule | Approved |
| Tgene | ESR1 | P03372 | DB00304 | Desogestrel | Agonist | Small molecule | Approved |
| Tgene | ESR1 | P03372 | DB00648 | Mitotane | Small molecule | Approved | |
| Tgene | ESR1 | P03372 | DB00648 | Mitotane | Small molecule | Approved | |
| Tgene | ESR1 | P03372 | DB00648 | Mitotane | Small molecule | Approved | |
| Tgene | ESR1 | P03372 | DB00655 | Estrone | Agonist | Small molecule | Approved |
| Tgene | ESR1 | P03372 | DB00655 | Estrone | Agonist | Small molecule | Approved |
| Tgene | ESR1 | P03372 | DB00655 | Estrone | Agonist | Small molecule | Approved |
| Tgene | ESR1 | P03372 | DB00675 | Tamoxifen | Agonist|Antagonist | Small molecule | Approved |
| Tgene | ESR1 | P03372 | DB00675 | Tamoxifen | Agonist|Antagonist | Small molecule | Approved |
| Tgene | ESR1 | P03372 | DB00675 | Tamoxifen | Agonist|Antagonist | Small molecule | Approved |
| Tgene | ESR1 | P03372 | DB00823 | Ethynodiol diacetate | Agonist | Small molecule | Approved |
| Tgene | ESR1 | P03372 | DB00823 | Ethynodiol diacetate | Agonist | Small molecule | Approved |
| Tgene | ESR1 | P03372 | DB00823 | Ethynodiol diacetate | Agonist | Small molecule | Approved |
| Tgene | ESR1 | P03372 | DB00841 | Dobutamine | Small molecule | Approved | |
| Tgene | ESR1 | P03372 | DB00841 | Dobutamine | Small molecule | Approved | |
| Tgene | ESR1 | P03372 | DB00841 | Dobutamine | Small molecule | Approved | |
| Tgene | ESR1 | P03372 | DB00977 | Ethinylestradiol | Agonist | Small molecule | Approved |
| Tgene | ESR1 | P03372 | DB00977 | Ethinylestradiol | Agonist | Small molecule | Approved |
| Tgene | ESR1 | P03372 | DB00977 | Ethinylestradiol | Agonist | Small molecule | Approved |
| Tgene | ESR1 | P03372 | DB01357 | Mestranol | Agonist | Small molecule | Approved |
| Tgene | ESR1 | P03372 | DB01357 | Mestranol | Agonist | Small molecule | Approved |
| Tgene | ESR1 | P03372 | DB01357 | Mestranol | Agonist | Small molecule | Approved |
| Tgene | ESR1 | P03372 | DB01406 | Danazol | Agonist | Small molecule | Approved |
| Tgene | ESR1 | P03372 | DB01406 | Danazol | Agonist | Small molecule | Approved |
| Tgene | ESR1 | P03372 | DB01406 | Danazol | Agonist | Small molecule | Approved |
| Tgene | ESR1 | P03372 | DB04574 | Estrone sulfate | Agonist | Small molecule | Approved |
| Tgene | ESR1 | P03372 | DB04574 | Estrone sulfate | Agonist | Small molecule | Approved |
| Tgene | ESR1 | P03372 | DB04574 | Estrone sulfate | Agonist | Small molecule | Approved |
| Tgene | ESR1 | P03372 | DB04575 | Quinestrol | Agonist|Modulator | Small molecule | Approved |
| Tgene | ESR1 | P03372 | DB04575 | Quinestrol | Agonist|Modulator | Small molecule | Approved |
| Tgene | ESR1 | P03372 | DB04575 | Quinestrol | Agonist|Modulator | Small molecule | Approved |
| Tgene | ESR1 | P03372 | DB06710 | Methyltestosterone | Small molecule | Approved | |
| Tgene | ESR1 | P03372 | DB06710 | Methyltestosterone | Small molecule | Approved | |
| Tgene | ESR1 | P03372 | DB06710 | Methyltestosterone | Small molecule | Approved | |
| Tgene | ESR1 | P03372 | DB09086 | Eugenol | Small molecule | Approved | |
| Tgene | ESR1 | P03372 | DB09086 | Eugenol | Small molecule | Approved | |
| Tgene | ESR1 | P03372 | DB09086 | Eugenol | Small molecule | Approved | |
| Tgene | ESR1 | P03372 | DB09317 | Synthetic Conjugated Estrogens, A | Ligand | Small molecule | Approved |
| Tgene | ESR1 | P03372 | DB09317 | Synthetic Conjugated Estrogens, A | Ligand | Small molecule | Approved |
| Tgene | ESR1 | P03372 | DB09317 | Synthetic Conjugated Estrogens, A | Ligand | Small molecule | Approved |
| Tgene | ESR1 | P03372 | DB09318 | Synthetic Conjugated Estrogens, B | Ligand | Small molecule | Approved |
| Tgene | ESR1 | P03372 | DB09318 | Synthetic Conjugated Estrogens, B | Ligand | Small molecule | Approved |
| Tgene | ESR1 | P03372 | DB09318 | Synthetic Conjugated Estrogens, B | Ligand | Small molecule | Approved |
| Tgene | ESR1 | P03372 | DB09369 | Polyestradiol phosphate | Agonist | Small molecule | Approved |
| Tgene | ESR1 | P03372 | DB09369 | Polyestradiol phosphate | Agonist | Small molecule | Approved |
| Tgene | ESR1 | P03372 | DB09369 | Polyestradiol phosphate | Agonist | Small molecule | Approved |
| Tgene | ESR1 | P03372 | DB09371 | Norethynodrel | Small molecule | Approved | |
| Tgene | ESR1 | P03372 | DB09371 | Norethynodrel | Small molecule | Approved | |
| Tgene | ESR1 | P03372 | DB09371 | Norethynodrel | Small molecule | Approved | |
| Tgene | ESR1 | P03372 | DB11219 | Enzacamene | Small molecule | Approved | |
| Tgene | ESR1 | P03372 | DB11219 | Enzacamene | Small molecule | Approved | |
| Tgene | ESR1 | P03372 | DB11219 | Enzacamene | Small molecule | Approved | |
| Tgene | ESR1 | P03372 | DB11619 | Gestrinone | Agonist|Antagonist | Small molecule | Approved |
| Tgene | ESR1 | P03372 | DB11619 | Gestrinone | Agonist|Antagonist | Small molecule | Approved |
| Tgene | ESR1 | P03372 | DB11619 | Gestrinone | Agonist|Antagonist | Small molecule | Approved |
| Tgene | ESR1 | P03372 | DB13943 | Testosterone cypionate | Small molecule | Approved | |
| Tgene | ESR1 | P03372 | DB13943 | Testosterone cypionate | Small molecule | Approved | |
| Tgene | ESR1 | P03372 | DB13943 | Testosterone cypionate | Small molecule | Approved | |
| Tgene | ESR1 | P03372 | DB13944 | Testosterone enanthate | Small molecule | Approved | |
| Tgene | ESR1 | P03372 | DB13944 | Testosterone enanthate | Small molecule | Approved | |
| Tgene | ESR1 | P03372 | DB13944 | Testosterone enanthate | Small molecule | Approved | |
| Tgene | ESR1 | P03372 | DB15690 | Fluoroestradiol F-18 | Binder | Small molecule | Approved |
| Tgene | ESR1 | P03372 | DB15690 | Fluoroestradiol F-18 | Binder | Small molecule | Approved |
| Tgene | ESR1 | P03372 | DB15690 | Fluoroestradiol F-18 | Binder | Small molecule | Approved |
| Tgene | ESR1 | P03372 | DB14548 | Zinc sulfate, unspecified form | Binder | Small molecule | Approved|Experimental |
| Tgene | ESR1 | P03372 | DB14548 | Zinc sulfate, unspecified form | Binder | Small molecule | Approved|Experimental |
| Tgene | ESR1 | P03372 | DB14548 | Zinc sulfate, unspecified form | Binder | Small molecule | Approved|Experimental |
| Tgene | ESR1 | P03372 | DB01185 | Fluoxymesterone | Antagonist | Small molecule | Approved|Illicit |
| Tgene | ESR1 | P03372 | DB01185 | Fluoxymesterone | Antagonist | Small molecule | Approved|Illicit |
| Tgene | ESR1 | P03372 | DB01185 | Fluoxymesterone | Antagonist | Small molecule | Approved|Illicit |
| Tgene | ESR1 | P03372 | DB00255 | Diethylstilbestrol | Agonist | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB00255 | Diethylstilbestrol | Agonist | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB00255 | Diethylstilbestrol | Agonist | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB00367 | Levonorgestrel | Other/unknown | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB00367 | Levonorgestrel | Other/unknown | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB00367 | Levonorgestrel | Other/unknown | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB00481 | Raloxifene | Agonist | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB00481 | Raloxifene | Agonist | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB00481 | Raloxifene | Agonist | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB00539 | Toremifene | Modulator | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB00539 | Toremifene | Modulator | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB00539 | Toremifene | Modulator | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB00603 | Medroxyprogesterone acetate | Agonist | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB00603 | Medroxyprogesterone acetate | Agonist | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB00603 | Medroxyprogesterone acetate | Agonist | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB00624 | Testosterone | Inhibitor | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB00624 | Testosterone | Inhibitor | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB00624 | Testosterone | Inhibitor | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB00882 | Clomifene | Agonist|Antagonist | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB00882 | Clomifene | Agonist|Antagonist | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB00882 | Clomifene | Agonist|Antagonist | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB00890 | Dienestrol | Agonist | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB00890 | Dienestrol | Agonist | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB00890 | Dienestrol | Agonist | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB00947 | Fulvestrant | Antagonist | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB00947 | Fulvestrant | Antagonist | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB00947 | Fulvestrant | Antagonist | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB00957 | Norgestimate | Agonist | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB00957 | Norgestimate | Agonist | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB00957 | Norgestimate | Agonist | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB01196 | Estramustine | Agonist | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB01196 | Estramustine | Agonist | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB01196 | Estramustine | Agonist | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB01428 | Oxybenzone | Small molecule | Approved|Investigational | |
| Tgene | ESR1 | P03372 | DB01428 | Oxybenzone | Small molecule | Approved|Investigational | |
| Tgene | ESR1 | P03372 | DB01428 | Oxybenzone | Small molecule | Approved|Investigational | |
| Tgene | ESR1 | P03372 | DB01593 | Zinc | Cofactor | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB01593 | Zinc | Cofactor | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB01593 | Zinc | Cofactor | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB04930 | Permethrin | Small molecule | Approved|Investigational | |
| Tgene | ESR1 | P03372 | DB04930 | Permethrin | Small molecule | Approved|Investigational | |
| Tgene | ESR1 | P03372 | DB04930 | Permethrin | Small molecule | Approved|Investigational | |
| Tgene | ESR1 | P03372 | DB04938 | Ospemifene | Agonist|Antagonist | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB04938 | Ospemifene | Agonist|Antagonist | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB04938 | Ospemifene | Agonist|Antagonist | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB06202 | Lasofoxifene | Agonist|Antagonist|Negative modulator | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB06202 | Lasofoxifene | Agonist|Antagonist|Negative modulator | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB06202 | Lasofoxifene | Agonist|Antagonist|Negative modulator | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB06249 | Arzoxifene | Small molecule | Approved|Investigational | |
| Tgene | ESR1 | P03372 | DB06249 | Arzoxifene | Small molecule | Approved|Investigational | |
| Tgene | ESR1 | P03372 | DB06249 | Arzoxifene | Small molecule | Approved|Investigational | |
| Tgene | ESR1 | P03372 | DB06401 | Bazedoxifene | Agonist|Antagonist | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB06401 | Bazedoxifene | Agonist|Antagonist | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB06401 | Bazedoxifene | Agonist|Antagonist | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB09070 | Tibolone | Agonist|Antagonist | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB09070 | Tibolone | Agonist|Antagonist | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB09070 | Tibolone | Agonist|Antagonist | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB09535 | Octocrylene | Small molecule | Approved|Investigational | |
| Tgene | ESR1 | P03372 | DB09535 | Octocrylene | Small molecule | Approved|Investigational | |
| Tgene | ESR1 | P03372 | DB09535 | Octocrylene | Small molecule | Approved|Investigational | |
| Tgene | ESR1 | P03372 | DB11064 | Homosalate | Small molecule | Approved|Investigational | |
| Tgene | ESR1 | P03372 | DB11064 | Homosalate | Small molecule | Approved|Investigational | |
| Tgene | ESR1 | P03372 | DB11064 | Homosalate | Small molecule | Approved|Investigational | |
| Tgene | ESR1 | P03372 | DB13946 | Testosterone undecanoate | Small molecule | Approved|Investigational | |
| Tgene | ESR1 | P03372 | DB13946 | Testosterone undecanoate | Small molecule | Approved|Investigational | |
| Tgene | ESR1 | P03372 | DB13946 | Testosterone undecanoate | Small molecule | Approved|Investigational | |
| Tgene | ESR1 | P03372 | DB14487 | Zinc acetate | Small molecule | Approved|Investigational | |
| Tgene | ESR1 | P03372 | DB14487 | Zinc acetate | Small molecule | Approved|Investigational | |
| Tgene | ESR1 | P03372 | DB14487 | Zinc acetate | Small molecule | Approved|Investigational | |
| Tgene | ESR1 | P03372 | DB14533 | Zinc chloride | Binder | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB14533 | Zinc chloride | Binder | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB14533 | Zinc chloride | Binder | Small molecule | Approved|Investigational |
| Tgene | ESR1 | P03372 | DB01708 | Prasterone | Binder | Small molecule | Approved|Investigational|Nutraceutical |
| Tgene | ESR1 | P03372 | DB01708 | Prasterone | Binder | Small molecule | Approved|Investigational|Nutraceutical |
| Tgene | ESR1 | P03372 | DB01708 | Prasterone | Binder | Small molecule | Approved|Investigational|Nutraceutical |
| Tgene | ESR1 | P03372 | DB00783 | Estradiol | Agonist | Small molecule | Approved|Investigational|Vet_approved |
| Tgene | ESR1 | P03372 | DB00783 | Estradiol | Agonist | Small molecule | Approved|Investigational|Vet_approved |
| Tgene | ESR1 | P03372 | DB00783 | Estradiol | Agonist | Small molecule | Approved|Investigational|Vet_approved |
| Tgene | ESR1 | P03372 | DB04573 | Estriol | Agonist | Small molecule | Approved|Investigational|Vet_approved |
| Tgene | ESR1 | P03372 | DB04573 | Estriol | Agonist | Small molecule | Approved|Investigational|Vet_approved |
| Tgene | ESR1 | P03372 | DB04573 | Estriol | Agonist | Small molecule | Approved|Investigational|Vet_approved |
| Tgene | ESR1 | P03372 | DB13952 | Estradiol acetate | Agonist | Small molecule | Approved|Investigational|Vet_approved |
| Tgene | ESR1 | P03372 | DB13952 | Estradiol acetate | Agonist | Small molecule | Approved|Investigational|Vet_approved |
| Tgene | ESR1 | P03372 | DB13952 | Estradiol acetate | Agonist | Small molecule | Approved|Investigational|Vet_approved |
| Tgene | ESR1 | P03372 | DB13953 | Estradiol benzoate | Agonist | Small molecule | Approved|Investigational|Vet_approved |
| Tgene | ESR1 | P03372 | DB13953 | Estradiol benzoate | Agonist | Small molecule | Approved|Investigational|Vet_approved |
| Tgene | ESR1 | P03372 | DB13953 | Estradiol benzoate | Agonist | Small molecule | Approved|Investigational|Vet_approved |
| Tgene | ESR1 | P03372 | DB13954 | Estradiol cypionate | Agonist | Small molecule | Approved|Investigational|Vet_approved |
| Tgene | ESR1 | P03372 | DB13954 | Estradiol cypionate | Agonist | Small molecule | Approved|Investigational|Vet_approved |
| Tgene | ESR1 | P03372 | DB13954 | Estradiol cypionate | Agonist | Small molecule | Approved|Investigational|Vet_approved |
| Tgene | ESR1 | P03372 | DB13955 | Estradiol dienanthate | Agonist | Small molecule | Approved|Investigational|Vet_approved |
| Tgene | ESR1 | P03372 | DB13955 | Estradiol dienanthate | Agonist | Small molecule | Approved|Investigational|Vet_approved |
| Tgene | ESR1 | P03372 | DB13955 | Estradiol dienanthate | Agonist | Small molecule | Approved|Investigational|Vet_approved |
| Tgene | ESR1 | P03372 | DB13956 | Estradiol valerate | Agonist | Small molecule | Approved|Investigational|Vet_approved |
| Tgene | ESR1 | P03372 | DB13956 | Estradiol valerate | Agonist | Small molecule | Approved|Investigational|Vet_approved |
| Tgene | ESR1 | P03372 | DB13956 | Estradiol valerate | Agonist | Small molecule | Approved|Investigational|Vet_approved |
| Tgene | ESR1 | P03372 | DB01108 | Trilostane | Allosteric modulator | Small molecule | Approved|Investigational|Vet_approved|Withdrawn |
| Tgene | ESR1 | P03372 | DB01108 | Trilostane | Allosteric modulator | Small molecule | Approved|Investigational|Vet_approved|Withdrawn |
| Tgene | ESR1 | P03372 | DB01108 | Trilostane | Allosteric modulator | Small molecule | Approved|Investigational|Vet_approved|Withdrawn |
| Tgene | ESR1 | P03372 | DB01065 | Melatonin | Antagonist | Small molecule | Approved|Nutraceutical|Vet_approved |
| Tgene | ESR1 | P03372 | DB01065 | Melatonin | Antagonist | Small molecule | Approved|Nutraceutical|Vet_approved |
| Tgene | ESR1 | P03372 | DB01065 | Melatonin | Antagonist | Small molecule | Approved|Nutraceutical|Vet_approved |
| Tgene | ESR1 | P03372 | DB00396 | Progesterone | Agonist|Downregulator|Inhibitor | Small molecule | Approved|Vet_approved |
| Tgene | ESR1 | P03372 | DB00396 | Progesterone | Agonist|Downregulator|Inhibitor | Small molecule | Approved|Vet_approved |
| Tgene | ESR1 | P03372 | DB00396 | Progesterone | Agonist|Downregulator|Inhibitor | Small molecule | Approved|Vet_approved |
| Tgene | ESR1 | P03372 | DB01183 | Naloxone | Antagonist|Other/unknown | Small molecule | Approved|Vet_approved |
| Tgene | ESR1 | P03372 | DB01183 | Naloxone | Antagonist|Other/unknown | Small molecule | Approved|Vet_approved |
| Tgene | ESR1 | P03372 | DB01183 | Naloxone | Antagonist|Other/unknown | Small molecule | Approved|Vet_approved |
| Tgene | ESR1 | P03372 | DB00431 | Lindane | Small molecule | Approved|Withdrawn | |
| Tgene | ESR1 | P03372 | DB00431 | Lindane | Small molecule | Approved|Withdrawn | |
| Tgene | ESR1 | P03372 | DB00431 | Lindane | Small molecule | Approved|Withdrawn | |
| Tgene | ESR1 | P03372 | DB00756 | Hexachlorophene | Small molecule | Approved|Withdrawn | |
| Tgene | ESR1 | P03372 | DB00756 | Hexachlorophene | Small molecule | Approved|Withdrawn | |
| Tgene | ESR1 | P03372 | DB00756 | Hexachlorophene | Small molecule | Approved|Withdrawn | |
| Tgene | ESR1 | P03372 | DB04824 | Phenolphthalein | Agonist | Small molecule | Approved|Withdrawn |
| Tgene | ESR1 | P03372 | DB04824 | Phenolphthalein | Agonist | Small molecule | Approved|Withdrawn |
| Tgene | ESR1 | P03372 | DB04824 | Phenolphthalein | Agonist | Small molecule | Approved|Withdrawn |
| Tgene | ESR1 | P03372 | DB11478 | Zeranol | Small molecule | Experimental|Vet_approved | |
| Tgene | ESR1 | P03372 | DB11478 | Zeranol | Small molecule | Experimental|Vet_approved | |
| Tgene | ESR1 | P03372 | DB11478 | Zeranol | Small molecule | Experimental|Vet_approved | |
| Tgene | ESR1 | P03372 | DB11541 | Ractopamine | Small molecule | Vet_approved | |
| Tgene | ESR1 | P03372 | DB11541 | Ractopamine | Small molecule | Vet_approved | |
| Tgene | ESR1 | P03372 | DB11541 | Ractopamine | Small molecule | Vet_approved |
Top |
Related Diseases for ARHGAP35-ESR1 |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
| Hgene | ARHGAP35 | C0152013 | Adenocarcinoma of lung (disorder) | 1 | CTD_human |
| Tgene | ESR1 | C0006142 | Malignant neoplasm of breast | 14 | CGI;CTD_human;GENOMICS_ENGLAND;UNIPROT |
| Tgene | ESR1 | C0678222 | Breast Carcinoma | 14 | CGI;CTD_human |
| Tgene | ESR1 | C1257931 | Mammary Neoplasms, Human | 14 | CTD_human |
| Tgene | ESR1 | C1458155 | Mammary Neoplasms | 14 | CTD_human |
| Tgene | ESR1 | C4704874 | Mammary Carcinoma, Human | 14 | CTD_human |
| Tgene | ESR1 | C0005586 | Bipolar Disorder | 5 | PSYGENET |
| Tgene | ESR1 | C0011570 | Mental Depression | 5 | PSYGENET |
| Tgene | ESR1 | C0011581 | Depressive disorder | 5 | PSYGENET |
| Tgene | ESR1 | C0036341 | Schizophrenia | 5 | PSYGENET |
| Tgene | ESR1 | C0525045 | Mood Disorders | 4 | PSYGENET |
| Tgene | ESR1 | C3809250 | ESTROGEN RESISTANCE | 3 | GENOMICS_ENGLAND;ORPHANET;UNIPROT |
| Tgene | ESR1 | C0001418 | Adenocarcinoma | 2 | CTD_human |
| Tgene | ESR1 | C0007097 | Carcinoma | 2 | CTD_human |
| Tgene | ESR1 | C0007621 | Neoplastic Cell Transformation | 2 | CTD_human |
| Tgene | ESR1 | C0010054 | Coronary Arteriosclerosis | 2 | CTD_human |
| Tgene | ESR1 | C0021364 | Male infertility | 2 | CTD_human |
| Tgene | ESR1 | C0024121 | Lung Neoplasms | 2 | CTD_human |
| Tgene | ESR1 | C0024667 | Animal Mammary Neoplasms | 2 | CTD_human |
| Tgene | ESR1 | C0025500 | Mesothelioma | 2 | CTD_human |
| Tgene | ESR1 | C0027626 | Neoplasm Invasiveness | 2 | CTD_human |
| Tgene | ESR1 | C0033578 | Prostatic Neoplasms | 2 | CTD_human |
| Tgene | ESR1 | C0205641 | Adenocarcinoma, Basal Cell | 2 | CTD_human |
| Tgene | ESR1 | C0205642 | Adenocarcinoma, Oxyphilic | 2 | CTD_human |
| Tgene | ESR1 | C0205643 | Carcinoma, Cribriform | 2 | CTD_human |
| Tgene | ESR1 | C0205644 | Carcinoma, Granular Cell | 2 | CTD_human |
| Tgene | ESR1 | C0205645 | Adenocarcinoma, Tubular | 2 | CTD_human |
| Tgene | ESR1 | C0205696 | Anaplastic carcinoma | 2 | CTD_human |
| Tgene | ESR1 | C0205697 | Carcinoma, Spindle-Cell | 2 | CTD_human |
| Tgene | ESR1 | C0205698 | Undifferentiated carcinoma | 2 | CTD_human |
| Tgene | ESR1 | C0205699 | Carcinomatosis | 2 | CTD_human |
| Tgene | ESR1 | C0242379 | Malignant neoplasm of lung | 2 | CTD_human |
| Tgene | ESR1 | C0376358 | Malignant neoplasm of prostate | 2 | CTD_human |
| Tgene | ESR1 | C0848676 | Subfertility, Male | 2 | CTD_human |
| Tgene | ESR1 | C0917731 | Male sterility | 2 | CTD_human |
| Tgene | ESR1 | C1257925 | Mammary Carcinoma, Animal | 2 | CTD_human |
| Tgene | ESR1 | C1956346 | Coronary Artery Disease | 2 | CTD_human |
| Tgene | ESR1 | C2239176 | Liver carcinoma | 2 | CTD_human |
| Tgene | ESR1 | C0002395 | Alzheimer's Disease | 1 | CTD_human |
| Tgene | ESR1 | C0004114 | Astrocytoma | 1 | CTD_human |
| Tgene | ESR1 | C0004153 | Atherosclerosis | 1 | CTD_human |
| Tgene | ESR1 | C0005684 | Malignant neoplasm of urinary bladder | 1 | CTD_human |
| Tgene | ESR1 | C0005695 | Bladder Neoplasm | 1 | CTD_human |
| Tgene | ESR1 | C0005940 | Bone Diseases | 1 | CTD_human |
| Tgene | ESR1 | C0005944 | Metabolic Bone Disorder | 1 | CTD_human |
| Tgene | ESR1 | C0007852 | Cervical Migraine Syndrome | 1 | CTD_human |
| Tgene | ESR1 | C0011265 | Presenile dementia | 1 | CTD_human |
| Tgene | ESR1 | C0014170 | Endometrial Neoplasms | 1 | CTD_human |
| Tgene | ESR1 | C0017658 | Glomerulonephritis | 1 | CTD_human |
| Tgene | ESR1 | C0018984 | Hemicrania migraine | 1 | CTD_human |
| Tgene | ESR1 | C0021361 | Female infertility | 1 | CTD_human |
| Tgene | ESR1 | C0023267 | Fibroid Tumor | 1 | CTD_human |
| Tgene | ESR1 | C0023418 | leukemia | 1 | CTD_human |
| Tgene | ESR1 | C0023903 | Liver neoplasms | 1 | CTD_human |
| Tgene | ESR1 | C0024668 | Mammary Neoplasms, Experimental | 1 | CTD_human |
| Tgene | ESR1 | C0024809 | Marijuana Abuse | 1 | PSYGENET |
| Tgene | ESR1 | C0026858 | Musculoskeletal Pain | 1 | CTD_human |
| Tgene | ESR1 | C0027051 | Myocardial Infarction | 1 | CTD_human |
| Tgene | ESR1 | C0027627 | Neoplasm Metastasis | 1 | CTD_human |
| Tgene | ESR1 | C0027643 | Neoplasm Recurrence, Local | 1 | CTD_human |
| Tgene | ESR1 | C0027819 | Neuroblastoma | 1 | CTD_human |
| Tgene | ESR1 | C0028754 | Obesity | 1 | CTD_human |
| Tgene | ESR1 | C0028960 | Oligospermia | 1 | CTD_human |
| Tgene | ESR1 | C0029453 | Osteopenia | 1 | CTD_human |
| Tgene | ESR1 | C0033937 | Psychoses, Drug | 1 | CTD_human |
| Tgene | ESR1 | C0033941 | Psychoses, Substance-Induced | 1 | CTD_human |
| Tgene | ESR1 | C0036939 | Shared Paranoid Disorder | 1 | PSYGENET |
| Tgene | ESR1 | C0038279 | Sterility, Postpartum | 1 | CTD_human |
| Tgene | ESR1 | C0042133 | Uterine Fibroids | 1 | CTD_human |
| Tgene | ESR1 | C0149931 | Migraine Disorders | 1 | CTD_human |
| Tgene | ESR1 | C0205768 | Subependymal Giant Cell Astrocytoma | 1 | CTD_human |
| Tgene | ESR1 | C0235874 | Disease Exacerbation | 1 | CTD_human |
| Tgene | ESR1 | C0270858 | Abdominal Migraine | 1 | CTD_human |
| Tgene | ESR1 | C0276496 | Familial Alzheimer Disease (FAD) | 1 | CTD_human |
| Tgene | ESR1 | C0280783 | Juvenile Pilocytic Astrocytoma | 1 | CTD_human |
| Tgene | ESR1 | C0280785 | Diffuse Astrocytoma | 1 | CTD_human |
| Tgene | ESR1 | C0282612 | Prostatic Intraepithelial Neoplasias | 1 | CTD_human |
| Tgene | ESR1 | C0334579 | Anaplastic astrocytoma | 1 | CTD_human |
| Tgene | ESR1 | C0334580 | Protoplasmic astrocytoma | 1 | CTD_human |
| Tgene | ESR1 | C0334581 | Gemistocytic astrocytoma | 1 | CTD_human |
| Tgene | ESR1 | C0334582 | Fibrillary Astrocytoma | 1 | CTD_human |
| Tgene | ESR1 | C0334583 | Pilocytic Astrocytoma | 1 | CTD_human |
| Tgene | ESR1 | C0338070 | Childhood Cerebral Astrocytoma | 1 | CTD_human |
| Tgene | ESR1 | C0338489 | Status Migrainosus | 1 | CTD_human |
| Tgene | ESR1 | C0341869 | Subfertility, Female | 1 | CTD_human |
| Tgene | ESR1 | C0345904 | Malignant neoplasm of liver | 1 | CTD_human |
| Tgene | ESR1 | C0476089 | Endometrial Carcinoma | 1 | CGI;CTD_human |
| Tgene | ESR1 | C0494463 | Alzheimer Disease, Late Onset | 1 | CTD_human |
| Tgene | ESR1 | C0521664 | Acute Confusional Migraine | 1 | CTD_human |
| Tgene | ESR1 | C0546126 | Acute Confusional Senile Dementia | 1 | CTD_human |
| Tgene | ESR1 | C0547065 | Mixed oligoastrocytoma | 1 | CTD_human |
| Tgene | ESR1 | C0700438 | Sick Headaches | 1 | CTD_human |
| Tgene | ESR1 | C0750900 | Alzheimer's Disease, Focal Onset | 1 | CTD_human |
| Tgene | ESR1 | C0750901 | Alzheimer Disease, Early Onset | 1 | CTD_human |
| Tgene | ESR1 | C0750935 | Cerebral Astrocytoma | 1 | CTD_human |
| Tgene | ESR1 | C0750936 | Intracranial Astrocytoma | 1 | CTD_human |
| Tgene | ESR1 | C0917730 | Female sterility | 1 | CTD_human |
| Tgene | ESR1 | C1563937 | Atherogenesis | 1 | CTD_human |
| Tgene | ESR1 | C1704230 | Grade I Astrocytoma | 1 | CTD_human |
| Tgene | ESR1 | C1704377 | Bright Disease | 1 | CTD_human |
| Tgene | ESR1 | C1720887 | Female Urogenital Diseases | 1 | CTD_human |
| Tgene | ESR1 | C1800706 | Idiopathic Pulmonary Fibrosis | 1 | CTD_human |
| Tgene | ESR1 | C4721508 | Hamman-Rich Disease | 1 | CTD_human |
| Tgene | ESR1 | C4721509 | Usual Interstitial Pneumonia | 1 | CTD_human |
| Tgene | ESR1 | C4721952 | Familial Idiopathic Pulmonary Fibrosis | 1 | CTD_human |
Copyright 2021-Present -The University of Texas Health Science Center at Houston (UTHealth)
Web File Viewing | Emergency Information |Campus Carry|Site Policies